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71. INTRODUCTION
Insulin-dependent diabetes mellitus (IDDM) is a chronic endocrine disease
characterized by severe loss of insulin secretion and hyperglycemia associated
with considerable morbidity, reduced life expectancy and significant health costs.
The incidence of IDDM in childhood is highest in Finland and it has increased
about 3-fold over the last four decades.
IDDM is strongly associated with autoimmune phenomena connected to
the loss of β-cells in the pancreatic islets. Several views on the pathogenic
mechanisms leading to destruction of the pancreatic β-cells have been proposed.
According to the most widely accepted hypothesis, IDDM is considered a T cell
mediated autoimmune disease in which a genetic predisposition is an important
prerequisite allowing the autoimmune process to progress. In this model, various
environmental factors have been proposed to trigger the autoimmune process, but
the nature of the factor(s) initiating the islet autoimmunity remains to be
established.
Considerable progress has been made over the last two decades in research
leading to a better understanding of the natural course of IDDM and
identification of individuals with a high risk for progression to the disease, but
the precise mechanisms leading to the destruction of pancreatic β-cells and overt
IDDM still remain unclear. Although the important role of cell mediated
immunity in the pathogenesis of IDDM is widely accepted, studies on the
characteristics of cellular immunity against suspected environmental or
autoantigens in human IDDM are few. A great challenge for future research is a
better understanding of the mechanisms and factors underlying IDDM, hopefully
providing means for preventing this disease.
82. REVIEW OF THE LITERATURE
2.1 Clinical aspects of IDDM
Diabetes mellitus is a state of absolute or relative insulin deficiency causing the
body to lose its ability to utilize carbohydrates as fuel. As a consequence glucose
levels are elevated in the blood and spill into the urine, and fat and proteins are
utilized to supply the body’s energy. IDDM (insulin-dependent diabetes mellitus,
type 1 diabetes) is thought to be a consequence of an autoimmune process which
progressively destroys the pancreatic β-cells leading to the need for insulin
replacement therapy. IDDM becomes clinically symptomatic when approximately
80-85% of the pancreatic β-cells are destroyed, insulin deficiency supervenes and
blood glucose levels rise to pathological levels. Epidemiological incidence
studies define the ”onset of IDDM” by the date of the first insulin injection
because of the variable time between the onset of symptoms and diagnosis.
Immunological markers permit the prediction of IDDM during the preclinical
stages of the disease in a number of individuals. The pathological process leading
to IDDM may start years before clinical symptoms become manifest. (Consensus
guidelines, ISPAD 1995.)
2.2 Pathogenesis of IDDM
2.2.1 The concept of IDDM as an autoimmune disease
The first evidence of the role of autoimmune mechanisms in the destruction of
pancreatic β-cells leading to IDDM came from examinations of pancreases from
patients with newly diagnosed IDDM, which revealed an infiltration of islets by
mononuclear lymphocytes (Gepts 1965), a condition known as insulitis. The next
step towards the acceptance of IDDM as an autoimmune disorder was the
description of islet cell autoantibodies (ICA), i.e. sera from IDDM patients were
shown to react with pancreatic islets by the indirect immunofluorescence
technique (Bottazzo et al. 1974). The third step was the identification of the
genetic markers for IDDM, especially the association of IDDM with specific
HLA class II alleles (Solow et al. 1979, Sachs et al. 1980). The fourth line of
evidence came from randomized trials with immunosuppressive agents inducing
remission of insulin-dependence in terms of insulin requirement or C-peptide
secretion (Harrison et al. 1985, Silverstein et al. 1988). The autoimmune nature
9of IDDM is further supported by its association with other known autoimmune
diseases (Kontiainen et al. 1990).
The autoimmune nature of diabetes is further supported by experiments in
nonobese diabetic (NOD) mice, which spontaneously develop diabetes closely
resembling human IDDM. Insulitis and diabetes can be adoptively transferred
with T lymphocytes from diabetic mice into non-diabetic recipients (Wicker et al.
1986, Bendelac et al. 1987, Christianson et al. 1993, Peterson et al. 1994).
2.2.2 Insulitis
Gepts’ classic paper (1965) describing insulitis was the first one excluding
patients with type 2 diabetes and clearly concentrating on the pancreases of newly
diagnosed IDDM patients. He described the insulitis in 15 of 22 such cases, and
speculated that this finding would be compatible with either a viral or an
autoimmune etiology of the disease, which still remain the possible theories. In
the mid 1960’s mononuclear cell infiltrates in pancreatic islets were described in
the islets of rabbits made diabetic by immunization with beef insulin (Grodsky et
al. 1966, Toreson et al. 1968), but not in the islets of animals with other forms of
experimental diabetes at that time.
The inflammatory infiltrate in islets consists mostly of T lymphocytes, but
the data on the predominance of CD4+ (Conrad et al. 1994) or CD8+ (Bottazzo et
al. 1985, Hänninen et al. 1992) T cells are discordant. A variable number of B
lymphocytes (Hänninen et al. 1992) and macrophages (Foulis et al. 1991,
Hänninen et al. 1992, Itoh et al. 1993) have also been described in the
inflammatory infiltrate.
Increased expression of HLA class I molecules has been described on the
β-cells as well as in other endocrine cells in inflamed islets (Hänninen et al. 1992,
Somoza et al. 1994). HLA class II expression has been described not only on
human β-cells but also on α- and δ-cells in vitro in the presence of interferon-γ
(IFN-γ) and tumor necrosis factor (TNF) or lymphotoxin (Pujol-Borrell et al.
1987). Class II-positive cells containing insulin have been detected in pancreases
from newly diagnosed IDDM patients (Foulis et al. 1987). However, electron
microscopy of BB rat islets revealed that insulin-containing, class II positive cells
were in fact macrophages which had phagocytosed β-cells, rather than HLA class
II expressing β-cells (In't Veld and Pipeleers 1988). Since data on the expression
of HLA class II molecules on pancreatic β-cells are not consistent, it remains
unanswered whether the expression of HLA class II molecules on endocrine cells
(if it exists) is a consequence of the autoimmune process (Weetman 1995) or
whether it is the cause of it (Todd and Bottazzo 1995).
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Vascular endothelium of the islets from patients with newly diagnosed
IDDM has been shown to overexpress HLA class II molecules and the
intercellular adhesion molecule (ICAM)-1 thus confirming that vascular
endothelium is activated during insulitis (Hänninen et al. 1992, Itoh et al. 1993).
Studies on T cell receptor (TCR) usage of the islet infiltrating lymphocytes have
been discrepant. In a study by Hänninen et al. (1992) Vβ8 T cells were most
abundant, whereas a study by Conrad and Trucco (1994) showed an exceptionally
high level (25-30%) expression of the Vβ7 family in two patients with newly
diagnosed IDDM. In the later study, Vβ7+ T cell clones among peripheral blood
lymphocytes from non-diabetic individuals showed positive selection and
expansion after exposure to diabetic islet cell membrane preparation. The authors
concluded that these findings point to the involvement of a superantigen rather
than a conventional antigen in the etiology of IDDM (Conrad and Trucco 1994).
2.2.3 Autoantigens
Islet cell autoantibodies (ICA) reacting with antigens located in the cytoplasm of
all endocrine cells within the pancreatic islets were first described more than two
decades ago (Bottazzo et al. 1974). By now, more than 10 candidate antigens as
the targets of these antibodies have been characterized. Furthermore, there is at
least one recent report on a new putative antigen, identified only by its apparent
molecular weight (McEvoy et al. 1996), suggesting that the number of the β-cell
targets of ICA will be increasing in the future.
2.2.3.1 GAD
Autoantibodies to a 64 kD islet cell protein were described in IDDM patients in
the early 1980’s (Baekkeskov et al. 1982). This protein was later identified as the
enzyme glutamic acid decarboxylase (GAD), which catalyses the formation of
main neuroinhibitor γ-aminobutyric acid (GABA) from L-glutamate (Baekkeskov
et al. 1990). There are two isoforms of GAD, of molecular weight 65 kD
(GAD65) and 67 kD (GAD67), which are both expressed in mammalian central
nervous system (Erlander and Tobin 1991). Rat and human islets express GAD65
predominantly or exclusively (Karlsen et al. 1992, Hagopian et al. 1993, Mally et
al. 1996b), whereas mouse islets express both isoforms of GAD at lower levels
than human islets, and GAD67 appears to predominate (Kim et al. 1993).
When GAD was discovered to be associated to IDDM, it was thought that
it would exist only in β-cells in the islets and thus explain the selective
destruction of β-cells (Baekkeskov et al. 1990), but Vives-Pi et al. showed that
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GAD is also expressed in 69% of α-cells and in 27% of δ-cells, although at a
lower level than in β-cells (Vives-Pi et al. 1993). The authors failed to detect
GAD on the cell membrane of any islet cell type, arguing against the possibility
that normal β-cells would express GAD selectively on their surface. However, it
should be emphasized that no pancreas from prediabetic subjects or newly
diagnosed IDDM patients was included. The role of GAD and GABA in the islets
of Langerhans is still unclear (Okada 1986). Since GABAA-receptors are found in
α- and δ-cells, it has been proposed that GABA might be involved in the
paracrine signaling between pancreatic islet cells (Rorsman et al. 1989).
Shortly after the report that the 64 kD protein showed GAD activity
(Baekkeskov et al. 1990), several assays to detect GAD65 autoantibodies
(GADA) were developed including ELISA, enzymatic activity in
immunoprecipitates or radioimmunoassay (reviewed in Schranz and Lernmark
1998). The availability of recombinant GAD made it possible to label GAD with
either 35S, 3H or 14C, which led to the development of precise and reproducible
radioligand binding assays as demonstrated in two international standardization
workshops (Schmidli et al. 1994, Schmidli et al. 1995). In recent years huge
amounts of data on the prevalence of GADA in patients with newly diagnosed
IDDM, patients with long duration of diabetes, prediabetic subjects, ICA positive
first degree relatives of IDDM patients and healthy non-related subjects have
accumulated (Petersen et al. 1994a, Bingley et al. 1994, Bonifacio et al. 1995,
Hagopian et al. 1995, Bingley et al. 1997, Kulmala et al. 1998, Savola et al.
1998). Typically about 80% of the IDDM patients have GADA at diagnosis. It
has been suggested that the screening of GADA combined with other IDDM
associated autoantibodies (IAA, IA-2) could replace the traditional ICA assay in
the prediction of IDDM (Kulmala et al. 1998).
Cellular reactivity to GAD65 in patients with newly diagnosed IDDM and
in high-risk relatives has been reported in about half of the subjects (Atkinson et
al. 1992, Harrison et al. 1993, Atkinson et al. 1994, Durinovic-Bello et al. 1996).
Overlapping sets of synthetic peptides have been used to identify the T cell
epitopes of GAD65. Atkinson et al. (1994) reported that the major determinant of
GAD65 recognized by persons at increased risk for IDDM was a region of amino
acids (aa) 247-279, which has a significant similarity with the non-structural
protein 2C of a coxsackieviral (CV) peptide (aa 32-47). A similar finding was
reported also by others (Armstrong and Jones 1994), but one comprehensive
investigation of GAD65 epitopes in IDDM did not suggest the PEVKEK region
(which is the six aa homology region between GAD65 and CVB4) as a major
antigenic region (Lohmann et al. 1994). Further, in a study by Endl et al. (1997)
GAD65 reactive T cell lines responding to epitopes containing identical
sequences to CVB 2C protein were not detected (Endl et al. 1997), thus leaving
the question of cross-reactivity between CVB and GAD65 controversial.
12
GAD67 reactive T cells have also been demonstrated in both at-risk
relatives (41%) and in diabetic patients (38%) (Honeyman et al. 1993a). Later the
same authors reported that increased cellular reactivity towards the mid region of
GAD67 was a marker of late pre-clinical IDDM, but they added that it appeared
to reflect a more general, transient hyperimmune state preceding the diagnosis of
IDDM (Honeyman et al. 1997). An inverse correlation between antibodies to
GAD67 and T cell reactivity to GAD67 has been described, and the authors
proposed that T cell reactivity to islet cell antigens could be a better predictive
marker of IDDM than high level of autoantibodies (Harrison et al. 1993).
The importance of GAD as an islet autoantigen in the pathogenesis of
IDDM is further emphasized by the studies on NOD mice showing that immune
response to GAD65 develops at the same time as the onset of insulitis, and
diabetes could be prevented by a single intravenous or intrathymic injection of
GAD65 in 3-week-old NOD mice (Kaufman et al. 1993, Tisch et al. 1993).
Prevention or decreased incidence of IDDM in NOD mice following early
injection of GAD65 or GAD67 has since been reported also by other groups
(Petersen et al. 1994b, Elliott et al. 1994, Pleau et al. 1995, Tian et al. 1996). The
mechanism by which the injection of GAD affects the degree of β-cell
destruction and development of diabetes in NOD mice has been supposed to be a
shift from destructive Th1 type immunity against islets to Th2 type non-
destructive immune response (Tian et al. 1996, Solimena and De 1996, Tisch et
al. 1998).
2.2.3.2 Insulin
Insulin is a rational proposal for a target autoantigen in IDDM, since it is a β-cell
specific protein. Insulin autoantibodies (IAA) before insulin-treatment were first
described as early as 1963 (Pav et al. 1963), but IAA were not convincingly
demonstrated until 1983 when Palmer et al. did this using 125I-insulin in a
radioligand binding assay. This first persuasive report on IAA demonstrated that
elevated levels of IAA (≥ +5SD of control subjects mean) were present in the
sera of 16% of subjects with newly diagnosed IDDM (Palmer et al. 1983). Since
then, due to methodological differences, there were conflicting reports regarding
the prevalence of IAA in various subject groups and the value of IAA in
predicting the development of clinical IDDM. In the international standardization
workshops it was concluded that IAA measured by a fluid-phase
radioimmunoassay (RIA) were more related to IDDM than those measured by a
solid-phase enzyme-linked immunoabsorbent assay (ELISA) (Greenbaum et al.
1992).
Abundant studies in recent years on the prevalence of IAA in different
populations have led to the conclusion that the frequency of IAA is about 40-80%
13
at the diagnosis of IDDM (Landin-Olsson et al. 1992, Vähäsalo et al. 1996,
Bingley et al. 1997). A significant age-dependency has been described in the
prevalence of IAA in patients with newly diagnosed IDDM, IAA being more
common in young children than among adolescents or adults (Arslanian et al.
1985). IAA have been reported to be the first autoantibody to appear in offsprings
of diabetic mothers (Ziegler et al. 1999).
T cell reactivity to insulin has been described both in patients with IDDM
and in first degree relatives with ICA (Scheinin et al. 1988, Naquet et al. 1988,
Keller 1990). However, some degree of reactivity is present also in healthy
control subjects (Scheinin et al. 1988, Keller 1990). In general, the magnitude of
T cell reactivity to insulin tends to be low. A low frequency of the precursor cells
in peripheral blood (Schloot et al. 1998) is one possible reason for the difficulties
in attempts to demonstrate insulin reactive peripheral T cells.
Studies on NOD mice support the role of insulin as an autoantigen in
IDDM. In pre-diabetic NOD mice insulin-specific T cells have been shown to be
a predominant component of islet infiltrates (Wegmann et al. 1994), and it has
been possible to use insulin specific T clones to either accelerate diabetes in
young NOD mice or adoptively transfer the disease to NOD/SCID mice (Daniel
et al. 1995).
It has also been suggested that the insulin precursor, proinsulin, may be an
important autoantigen in IDDM, since in one study the proinsulin autoantibodies
were more closely associated with IDDM than IAA (Böhmer et al. 1991). It has
been reported that similar peptides from proinsulin and GAD stimulate T cells of
individuals at risk for IDDM (Rudy et al. 1995), further supporting the possible
role of proinsulin as an autoantigen in IDDM. However, quite recently one study
was published showing no evidence for enhanced T cell reactivity to proinsulin in
patients with IDDM (Ellis et al. 1999).
2.2.3.3 Protein tyrosine phosphatase like islet cell antigens IA-2 and IA-2β
Immunoprecipitation of insulinoma cell lysates with sera from IDDM patients
yielded a 64 kD protein which was distinct from GAD (Christie et al. 1993) and
which further in trypsin treatment resulted in 50 kD, 40 kD and 37 kD fragments.
Antibodies that bind to the 50 kD fragment were also found to immunoprecipitate
GAD65, whereas the 40 kD and 37 kD fragments appeared to be derivatives of a
different protein. Islet cell antigen 512 (ICA512) was independently identified
from an islet cell cDNA expression library by screening with sera from IDDM
patients (Rabin et al. 1992, Rabin et al. 1994). ICA512 was also isolated from a
human insulinoma expression library, and was designated islet cell antigen 2 (IA-
2) (Lan et al. 1994). The 3.6 kb cDNA of IA-2/ICA512 showed a 979 amino acid
protein homologous to protein tyrosine phosphatase-2 (PTP-2) (Lan et al. 1994,
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Lu et al. 1994). By now antibodies to IA-2 have been described in the majority of
IDDM patients, the reported prevalence being 62% (Hawa et al. 1997), 75%
(Bingley et al. 1997), or 86% (Savola et al. 1998).
IA-2 is a transmembrane protein, the extracellular and intracellular
domains being 576 and 378 amino acids in length, respectively (Lan et al. 1994,
Lan et al. 1996b). Interestingly, the major antigenic regions of IA-2 seem to be
located in the intracellular domain of the molecule; none of the sera from IDDM
patients reacted with the extracellular domain (Zhang et al. 1997). IA-2 is mainly
expressed in neuroendocrine cells. Although IA-2 is a member of the PTP family,
the expressed recombinant protein lacks the PTP enzyme activity (Rabin et al.
1994). The function of native IA-2 in islets is still not known. The IA-2 gene is
located on chromosome 2q35 (Lan et al. 1996a).
The above mentioned 37 kD fragment turned out to be identical with IA-
2β, another important autoantigen in IDDM. IA-2β is in many respects similar to
IA-2, especially in its intracellular domain which is 74% identical to IA-2
(Notkins et al. 1997). Antibodies to IA-2β are seen in approximately 45% of
IDDM patients (Lu et al. 1996, Notkins et al. 1997), the prevalence being lower
than that of IA-2, and since more than 95% of IDDM patients who have
antibodies against IA-2β also have IA-2 antibodies, screening for IA-2β
antibodies does not offer much advantage for clinical purposes.
Two recent studies have shown enhanced T cell reactivity to IA-2 in
patients with IDDM, but the level of stimulation has been low in almost all
subjects (Durinovic-Bello et al. 1996, Ellis et al. 1998b). A dominant epitope (aa
805-820) eliciting the highest T cell responses in all at-risk relatives was found in
a study for T cell epitope of IA-2 using overlapping peptides. This peptide has
56% identity and 100% similarity over nine amino acids with a sequence in VP7,
a major immunogenic protein of human rotavirus (Honeyman et al. 1998).
2.2.3.4 Others
In addition to GAD, insulin and IA-2, a number of other putative β-cell
autoantigens has been described. The islet cell antigen 69 (ICA69) was identified
by islet cDNA library screening (Pietropaolo et al. 1993). During recent years
ICA69 has been of special interest because it possesses sequence homology with
bovine serum albumin (BSA), a protein present in cow’s milk, which has been
proposed to be a possible environmental trigger of IDDM (Karjalainen et al.
1992). Later, it was demonstrated that ICA69 was widely expressed in human
tissues although highest in pancreas. Within the human pancreas, ICA69 was
expressed equally in endocrine and exocrine pancreas (Mally et al. 1996a).
ICA69 is identical with p69, an islet cell antigen identified by Western blotting of
rat islet cells with antibodies to BSA (Glerum et al. 1989).
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Carboxypeptidase H is another autoantigen identified by screening islet
expression libraries (Castano et al. 1991). Carboxypeptidase-H is a molecule
expressed within islet secretory granules and neuroendocrine cells, and it
facilitates the conversion of proinsulin to insulin.
Three distinct diabetes-associated autoantigens of 38 kD molecular mass
have been described. Honeyman et al. (1993b) reported the isolation of a cDNA
clone encoding a 38 kD nuclear transcription factor jun-B by antibody screening
of an expression library from islets and placenta using serum from an IDDM
patient. They subsequently detected T cell proliferation responses to jun-B in
some IDDM patients and their relatives. Another 38 kD autoantigen, Imogen 38,
was identified as a target for a CD4+ T cell clone from a patient with IDDM
(Arden et al. 1996). Imogen 38 is localized to mitochondria and has a wide tissue
distribution, and the authors concluded that Imogen 38 may be a target for
bystander autoimmune attack in IDDM rather than being a primary autoantigen
(Arden et al. 1996). The third 38 kD antigen was detected by
immunoprecipitation, and was named glima 38 (glycosylated islet cell membrane
antigen of 38 kD) (Aanstoot et al. 1996). Glima 38 is an amphiphilic membrane
glycoprotein specifically expressed in islet and neuronal cell lines. Glima 38
autoantibodies were detected in 19% of newly diagnosed IDDM patients.
In addition to the above mentioned autoantigens, still others have been
identified. Serum autoantibodies to glucose transporter-2 (GLUT-2) (Inman et al.
1993), to sulfatide (Buschard et al. 1993), and to ganglioside GM2-1 (Dotta et al.
1996) have been described in patients with newly diagnosed IDDM. One example
of new antigens identified only by their apparent molecular weights is a protein
of 138 kD, which is a membrane glycopeptide and a target of a monoclonal
antibody 1A2. Autoantibodies to this antigen inhibit the binding of a 1A2 to its
antigen, and are found in up to 87% of newly diagnosed IDDM patients and in
3.8% of control subjects (McEvoy et al. 1996). Undoubtedly, new autoantigens
will be identified in the future.
2.2.4 Cellular immunity in IDDM
2.2.4.1 Pathogenic role of T cells in IDDM
Transfer experiments in animal models for IDDM support the important role of T
cells in the pathogenesis of IDDM. Insulitis and diabetes can be adoptively
transferred with T lymphocytes from diabetic mice into non-diabetic recipients
(Wicker et al. 1986, Bendelac et al. 1987, Christianson et al. 1993, Peterson et al.
1994), whereas B cells are not needed (Bendelac et al. 1988). Autoantibodies
alone do not appear to be sufficient to induce β-cell destruction. Transplacentally
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transferred antibodies related to IDDM are usually eliminated from the peripheral
circulation of infants before 9 months of age (Martikainen et al. 1996), and in a
German follow-up study no difference was found in autoantibody frequencies
between the offsprings from mothers versus fathers with IDDM up to the age of 5
years (Ziegler et al. 1999).
The role of T cells in the pathogenesis of IDDM is further supported by
the findings that in the BB rat, β-cell destruction was prevented by neonatal
thymectomy (Like et al. 1982), and antibody treatment against surface markers
CD3 and CD4 delayed or prevented clinical diabetes (Shizuru et al. 1988,
Hutchings et al. 1992, Chatenoud et al. 1994).
In humans, bone marrow cells from subjects with IDDM transferred
IDDM into HLA-compatible siblings who received bone marrow transplantation
for the treatment of aplastic anemia or leukemia (Lampeter et al. 1993, Vialettes
et al. 1993). The role of T lymphocytes in the development of β-cell destruction
is further supported by the efficacy of immunosuppressive agents, which have
been shown to slow the progression of β-cell damage in patients with newly
diagnosed IDDM. These immunosuppressive agents include azathioprine
(Harrison et al. 1985, Silverstein et al. 1988) and cyclosporine (Feutren et al.
1986), and act mainly at the T cell level. Further, peripheral blood lymphocytes
from patients with IDDM proliferate in vitro on exposure to islet cell antigens
(discussed in chapter 2.2.3) indicating T cell mediated autoimmunity in IDDM.
Furthermore, the inflammatory lesion in the islets (insulitis) consists mostly of
mononuclear cells, mainly T lymphocytes and macrophages or monocytes as
discussed in chapter 2.2.2.
It is currently widely accepted that IDDM is an autoimmune disease in
which T cells play an important role. Although it has not been excluded that a
primary β-cell lesion might be involved in initiating an autoimmune response
(Wilkin 1990), by now there is no evidence that the target autoantigen in IDDM
or in other organ-specific autoimmune disease is abnormal. Rather, transfer
studies discussed previously demonstrate that bone marrow-derived cells can
transfer diabetes to non-diabetes-prone human, mouse or rat pancreases, thus
indicating that the abnormality resides in the immune system.
Abnormalities in lymphocyte subsets have been described in patients with
IDDM. An increased proportion of CD4 positive cells (Buschard et al. 1983a,
Ilonen et al. 1991, Peakman et al. 1994a) and a decreased proportion of CD8
positive cells (Buschard et al. 1983b) has been reported by several groups.
Further, there are studies showing that at diagnosis, patients with IDDM have
increased numbers of lymphocytes co-expressing the markers of naive (CD45RA)
and memory (CD45RO) cells (Smerdon et al. 1993, Peakman et al. 1994b,
Douglas Petersen et al. 1996). The functional implications of these abnormalities
are not yet known.
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2.2.4.2 Functional subtypes of T cells in IDDM
Antigen-activated CD4+ T cells are called T helper (Th) cells because they help to
mediate both cellular and humoral immune responses. At least two functionally
different subtypes of CD4+ Th cells, Th1 and Th2, have been described both in
mice (Mosmann et al. 1986) and in humans (Wierenga et al. 1991, Surcel et al.
1994). These Th subtypes differ from each other by their cytokine secretion
patterns. Th1 cells produce mostly IL-2 and IFN-γ, whereas Th2 cells produce IL-
4, IL-5, and IL-10. Th1 cells and their cytokine products are mediators in cellular
immunity, whereas Th2 cytokines are stimulators of humoral immune responses
and antibody production. Th1 and Th2 cytokines reciprocally regulate the
functions of each other (Powrie and Coffman 1993). Thus, the Th1 cytokine IFN-
γ inhibits the proliferation of Th2 but not Th1 cells (Gajewski and Fitch 1988),
and IL-10, via an effect of antigen presenting cells (APCs), inhibits the synthesis
of IFN-γ and other Th1 cytokines (Fiorentino et al. 1991). IL-4 also inhibits the
synthesis of IFN-γ by human peripheral blood mononuclear cells (PBMCs)
(Peleman et al. 1989). Cytokines secreted by Th1 cells have been shown to be
inhibitory to B cell proliferation and antibody production in vitro (Del Prete et al.
1991).
The paradigm of IDDM as a Th1 cell/cytokine mediated autoimmune
disease is mainly based on evidence in NOD mice and BB rats. In a study by
Healey et al. CD4+ T cell lines that reacted to rat insulinoma cells and secreted
either IFN-γ or IL-4 were generated from spleens of diabetic NOD mice. The
IFN-γ secreting CD4+ T cells adoptively transferred β-cell destructive insulitis
and diabetes in neonatal NOD mice, whereas the IL-4 secreting CD4+ T cells
induced a non-destructive peri-insulitis (Healey et al. 1995). Similarly, Th1 cells
expressing a diabetogenic TCR adoptively transferred β-cell destructive insulitis
and diabetes in neonatal NOD mice, whereas Th2 cells expressing the same
receptor did not; however, Th2 cells could not prevent the Th1 cells from
transferring diabetes (Katz et al. 1995). In other studies, a protective effect
against insulitis and diabetes in NOD mice has been demonstrated by treatments
with IL-4 (Rapoport et al. 1993), IL-4 producing T cells (Fowell and Mason
1993), and IL-10 (Pennline et al. 1994). Both IL-4 and IL-10 suppress IFN-γ
production (Powrie and Coffman 1993), and IFN-γ has been demonstrated to
cause or correlate with destructive insulitis and diabetes in animal models
(Campbell et al. 1991, Muir et al. 1995, Rabinovitch et al. 1995, Rabinovitch and
Suarez-Pinzon 1998).
Certain β-cell antigens act as autoantigens in IDDM. The immunogenicity
of an antigen depends on several factors including the nature of antigen
presenting cells (APCs), interaction of MHC and T cell receptor (TCR),
interaction of T cells with APC costimulatory molecules, and the precursor
frequency of autoreactive T cells. The direction of T cell response towards Th1 or
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Th2 phenotype is largely regulated by cytokines in the microenvironment. IL-4
favors Th2 differentiation (Seder et al. 1992), whereas the presence of IL-12
favors Th1 differentiation, and anti-IL-12 blocks it (Scott 1993). Administration
of IL-12 to prediabetic NOD female mice accelerated the development of
diabetes and this was associated with enhanced IFN-γ and decreased IL-4
secretion by islet infiltrating lymphocytes, and selective β-cell destruction
(Trembleau et al. 1995).
There are numerous studies showing that the administration of β-cell
antigens in diabetes prone animals have induced a shift from Th1 to Th2 activity
and thus prevented the development of diabetes (Solimena and De Camilli 1996,
Hartmann et al. 1997, Elias et al. 1997, Tisch et al. 1998, Tian et al. 1998).
It is not clear whether the paradigm of Th1 cell mediated β-cell destruction
applies to human IDDM. It should be emphasized that while studies on
experimental animals have focused on the local, intraislet, cytokine levels, such
studies are not possible in humans, and thus the functional subtypes of T cells and
possible Th1/Th2 deviation must be studied through cells obtained from
peripheral blood or by serum levels of different cytokines. Reports on serum
levels of cytokines in IDDM patients as well as cytokine production by
mononuclear cells in patients with IDDM are few. Serum levels of Th1 cytokines
(IFN-γ, IL-2) and monocyte derived cytokines (IL-1, TNF-α) have been reported
to be increased at the time of diagnosis in patients with IDDM (Hussain et al.
1996). Also there are studies showing no increase in serum levels of Th2
cytokines (IL-4 and IL-10) in patients with newly diagnosed IDDM (Cavallo et
al. 1991, Hussain et al. 1996). High levels of Th1 type cytokines IFN-γ and TNF-
α by mitogen stimulated PBMCs from diabetic patients have been reported
(Kallmann et al. 1997) as well as high levels of IL-1α and TNF-α both in patients
with IDDM and in healthy first degree relatives (Hussain et al. 1996). In one
study IL-4 production by PBMCs or T cells was low in patients with newly
diagnosed IDDM (Berman et al. 1996). Recently, there has been a report on a
strong deviation to Th1 type cytokine secretion by a particular subpopulation of T
cells (invariant Vα24JαQ T cells) from patients with IDDM, whereas this
subpopulation of T cells from healthy subjects and at-risk non-progressors
secreted both IL-4 and IFN-γ (Wilson et al. 1998). It is possible that deviation of
immune reactivity towards Th1 type responsiveness is an important determinant
for development of IDDM.
2.2.4.3 The role of cell adhesion molecules in the development of IDDM
The migration of autoreactive lymphocytes and other leukocytes from the
bloodstream into the pancreas is a prerequisite for the development of insulitis.
Lymphocyte migration from blood into tissue is a complex process involving a
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cascade of adhesion and activation steps (Butcher 1991, Springer 1994). This
migration is controlled in part by a selective expression of cell adhesion
molecules, so-called homing receptors, and their ligands, addressins, which are
expressed by cells of high endothelial venules (HEV) in tissues where
transedothelial migration of the lymphocytes into tissues takes place. Distinct
combinations of these adhesion molecules with their ligands make tissue-specific
migration possible. The cell adhesion molecules can be classified into at least
three groups based on their molecular structure: selectins, integrins and the
immunoglobulin superfamily (Springer 1990). Due to the scope of this review,
emphasis is put on the lymphocyte and endothelial cell adhesion molecules that
appear to be involved in the pathogenesis of IDDM (Yang et al. 1996).
L(leukocyte)-selectin is a member of the selectin family that is expressed
only in leukocytes. L-selectin is the principal peripheral lymph node homing
receptor and is present on all naive lymphocytes whereas memory cells show a
bimodal expression: a subpopulation expresses higher levels than naive cells,
whereas the rest are negative. L-selectin functions to mediate an initial and
transient attachment, or rolling, of leukocytes on vascular endothelial cells.
Peripheral lymph node specific addressins (PNAd) were the first characterized
counterreceptors for L-selectin. PNAd is predominantly expressed in HEV of
peripheral lymph nodes, but absent at mucosal and other sites. However, during
inflammation PNAd expression is inducible in non-peripheral node tissues (Yang
et al. 1996).
Integrins are a large family of heterodimeric cell surface adhesion
molecules that consist of non-covalently associated α- and β-chains. The α- and
β-chains are capable of associating in multiple combinations, thus forming
different kinds of heterodimers. α4β7-integrin has been shown to mediate
lymphocyte homing to mucosal sites such as Peyer’s patches via its ligand
mucosal addressin cell adhesion molecule (MAdCAM-1), which is expressed
mainly in mucosal lymphoid organ HEV and on the gut lamina propria venules
(Berlin et al. 1993). The β1-chain (CD29) can form heterodimers with several
integrin α-chains, previously known as very late antigens (VLAs). α4β1-integrin
has at least two distinct ligands: vascular cell adhesion molecule-1 (VCAM-1)
and the extracellular matrix protein fibronectin. VCAM-1 is a member of the Ig
family of adhesion molecules and is expressed in vivo by endothelial cells in
inflammatory sites (Osborn 1990). The β2-chain (CD18) can pair for instance
with the αL-chain to form αLβ2-integrin known as lymphocyte function associated
antigen-1 (LFA-1), which is expressed in all lymphocytes. LFA-1 is thought to
participate in the binding of lymphocytes to vascular endothelium in lymph
nodes, Peyer’s patches, and many extranodal sites of inflammation (Bargatze et
al. 1995, Hamann et al. 1988). The endothelial ligands for LFA-1 include ICAM-
1 and ICAM-2 (Springer 1990).
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In the light of the present literature, the α4β7-integrin seems to have a
predominant role in the pathogenesis of IDDM in NOD mice. MAdCAM-1 has
been reported to be expressed in endothelium of inflamed islets already at the
early stages of insulitis in NOD mice (Hänninen et al. 1993b, Faveeuw et al.
1994, Yang et al. 1994, Hänninen et al. 1996). In contrast, very little PNAd
expression is seen until there is significant insulitis (~8 weeks of age) (Hänninen
et al. 1993b, Faveeuw et al. 1994). While few L-selectin expressing lymphocytes
are seen in the islets during the early stages of insulitis, most infiltrating cells
express high levels of α4β7-integrin throughout the disease process. The
expression of α4β7-integrin correlates with high expression of MAdCAM-1 by
endothelial cells, further suggesting a predominant role for the mucosal homing
pathway in the development of insulitis (Hänninen et al. 1993b, Yang et al.
1994).
Studies with monoclonal antibodies against lymphocyte or endothelial cell
adhesion molecules have been carried out in vivo in an attempt to determine
which adhesion pathways are essential for the development of insulitis and
IDDM (reviewed in Yang et al. 1996). Treatment of neonatal NOD mice with
anti-L-selectin or anti-integrin α4 monoclonal antibodies for the first four weeks
of life led to significant and long term protection against spontaneous occurrence
of insulitis and diabetes. After the onset of insulitis from 10-14 weeks of age,
treatment with anti-L-selectin antibodies delayed the onset of but failed to
prevent spontaneous diabetes, whereas treatment with anti-integrin α4 antibodies
resulted in a significant and long-lasting suppression of the disease (Yang et al.
1994). Treatment of NOD mice with monoclonal antibodies against β7-integrin or
MAdCAM-1 from age 7 to 28 days or 8 to 12 weeks with either antibody led to
significant and long-standing protection against the spontaneous development of
diabetes and insulitis (Yang et al. 1997). In another recent study anti-MAdCAM-
1 treatment started at 3 weeks of age reduced the incidence of diabetes from 50%
to 9% and also inhibited both lymphocyte entry into the pancreas and diabetes
development in NOD/SCID recipients after the transfer of lymphocytes derived
from the mesenteric lymph nodes of young, but not of diabetic, NOD donors
(Hänninen et al. 1998). These results further indicate that the mucosal homing
pathway plays a role in the development of diabetes in NOD mice.
In humans, studies on the role of adhesion molecules in lymphocyte
homing to the islets are hampered by the limited availability of human pancreatic
tissue, particularly from prediabetic individuals. In one study a T-cell line was
propagated from pancreatic islets from a patient who died at the diagnosis of
IDDM. Interestingly, this cell line showed a strong adhesion to the endothelium
of mucosa-associated lymphoid tissues (Hänninen et al. 1993a).
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2.2.5 Molecular mechanisms of β-cell destruction
The precise mechanism by which β-cells die is not yet known. The β-cell antigen
specific immune response involves binding of CD8+ T cells to β-cells. The T
cells specifically recognize β-cell antigen presented by MHC class I molecules on
the β-cells. This is followed by activation of cytotoxic T cells, and these may kill
the β-cells by receptor (i.e. Fas/FasL) mediated mechanisms or by secretion of
cytotoxic molecules (perforin or granzymes) (Benoist and Mathis 1997). The
non-specific immune and inflammatory responses that destroy β-cells may be
mediated by molecules released by activated T cells and macrophages, such as
proinflammatory cytokines and free radicals. There is evidence that β-cells are
sensitive to injury mediated by oxygen free radicals and nitric oxide (Rabinovitch
and Suarez-Pinzon 1998). It is possible that both β-cell antigen specific and
nonspecific immune and inflammatory responses participate in mediating β-cell
destruction in IDDM (Kolb et al. 1995).
Whether β-cell death in IDDM is due to apoptosis or necrosis or a
combination of both has not been clarified (Mauricio and Mandrup-Poulsen
1998). Concerning the role of apoptosis there are two schools of thought.
According to one model β-cells are destroyed by cytotoxic T cells using effector
molecules of which perforin causes lysis of the target cell, whereas granzymes A
and B mainly cause apoptosis (Liu et al. 1996). Another model (Nerup et al.
1994, Mandrup-Poulsen 1996) hypothesizes that activated β-cell antigen specific
Th cells induce the build-up of a specific and nonspecific mononuclear cell
infiltrate and activate endothelial cells, which express adhesion molecules and
liberate inflammatory mediators. Recruited macrophages are stimulated by IFN-γ
to produce IL-1 and TNF-α, which in synergy with IFN-γ lead to β-cell toxicity
via apoptosis activating pathways. Further, the model implies that IL-1 leads to β-
cell Fas expression increasing the β-cell susceptibility to lysis by T cells
expressing FasL.
2.2.6 Genetic background
First evidence for the involvement of genetic factors in IDDM susceptibility
came from family studies showing a more frequent occurrence of the disease in
relatives of IDDM patients than in the general population. Monozygotic twins are
30-65% concordant with respect to IDDM (Olmos et al. 1988, Kumar et al.
1993), whereas for HLA identical siblings the risk for IDDM is approximately
20% (Cavender et al. 1984, Tarn et al. 1988). For the first degree relatives of
IDDM patients without stratification for genetic similarity the risk is
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approximately 6% (Thomson et al. 1988). Thus, it is clear that HLA genes play
an important role in IDDM susceptibility, but that also non-HLA genes make a
contribution.
2.2.6.1 HLA genes in IDDM susceptibility
The association between HLA antigens and IDDM was first described in 1973
(Singal and Blajchman 1973). The early studies showed an association between
serologically defined B8 and B15 HLA class I antigens and IDDM (Singal and
Blajchman 1973, Nerup et al. 1974), but when class II typing methods became
available, a stronger association was demonstrated between class II HLA Dw and
HLA DR alleles and IDDM (Solow et al. 1979, Sachs et al. 1980). HLA DR3
and/or HLA DR4 were found to be prevalent in approximately 95% of Caucasian
subjects with IDDM compared with 50-60% of non-diabetic individuals.
DR3/DR4 heterozygosity carries a particularly high risk for IDDM, since 30-50%
of subjects with IDDM but only 1-6% of healthy subjects carry this combination.
Since the primary observation of the association of Dw2 with resistance to IDDM
(Ilonen et al. 1978), DR2 antigen has been consistently associated with low risk
for IDDM (Wassmuth and Lernmark 1989, Deschamps and Khalil 1993).
Alleles of HLA DQ locus have later been implicated in IDDM
susceptibility (Owerbach et al. 1983, Nepom et al. 1986). It has been
demonstrated that of the DR4-associated DQB1 alleles only DQB1*0302 was
associated with IDDM whereas DQB1*0301 was not (Nepom et al. 1986, Morel
et al. 1988). Similarly it was shown that the DR2-DQB1*0602 haplotype was
highly protective, while the other DR2 haplotypes appeared to be neutral or only
slightly protective (Böhme et al. 1986). Since then many studies in Caucasian
populations have confirmed that DQB1*0302 confers IDDM susceptibility and
DQB1*0302/0201 heterozygosity represents the highest genetic risk for IDDM.
The HLA DQB1*0302 allele is found in approximately two thirds of Caucasian
IDDM patients compared to 20-30% of healthy controls (Nepom 1995, Ilonen et
al. 1996). DQB1*0302 and/or DQB1*0201 are found in 90-95% of children with
newly diagnosed IDDM compared with about 45-50% of healthy control subjects
(Lernmark 1994, Ilonen et al. 1996). The DQB1*0302/0201 heterozygosity is
found in 24-44% of IDDM patients but in less than 6% of healthy subjects
(Baisch et al. 1990, Reijonen et al. 1991, Ilonen et al. 1996).
2.2.6.2 The role of HLA molecules in autoimmunity
The major known function of HLA class II molecules is to bind and present
antigen-derived peptide fragments to T cells. Peptides derived from self proteins
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are presented by MHC class I molecules and recognized by CD8+ cells, whereas
class II molecules present (mainly non-self) peptides to CD4+ T cells. With
appropriate accessory signals this presentation leads to an immune response. Thus
the presentation of antigens to T cells by MHC molecules is crucial for the
regulation of peripheral immune responses. In the thymus both positive and
negative selection of T cell clones is based on the expression of HLA molecules
and adequate antigen presentation.
Several hypotheses have been introduced to explain the connection of
HLA genes to the development of IDDM. In 1990 Nepom presented a model in
which a diabetogenic peptide is permissive for disease when it binds to a disease
associated class II molecule, such as DQ3.2 (Nepom 1990). Environmental or
other genetic factors which upregulate expression of this class II susceptibility
gene or upregulate the antigen exposure and/or density of peptide class II
complexes on the APC are likely accelerating factors. Conversely, if the same
peptide is preferentially bound by higher avidity for class II molecules from a
protective genotype this may facilitate deviation of the immune response towards
a protective immunity. Another model presented by Sheehy focused on the failure
of the immune system to maintain tolerance to β-cells in IDDM (Sheehy 1992).
Recently Nepom and Kwok (1998) introduced a model for a pathway in which
the HLA DQ genes associated with IDDM bias the immunologic repertoire
toward autoimmune specificities, creating an autoimmune prone individual,
followed by amplification and triggering events that promote subsequent immune
activation. According to the current paradigm on the selection of T cells in the
thymus, the avidity of the TCR-HLA-peptide complex determines T cell selection
outcome: immature T cells that fail to interact with MHC molecules are not
selected, TCRs that surpass an avidity threshold are positively selected and the T
cells with high avidity are deleted. Thus exceptional stability of the HLA-
DQA1*0102/DQB1*0602 αβ protein dimer, which is associated with protection
from IDDM, could lead to higher avidity of TCR-HLA-peptide interaction and
subsequently negative selection of potentially autoreactive T cells in the thymus
(Ettinger et al. 1998, Nepom and Kwok 1998).
2.2.6.3 Other genes in IDDM susceptibility
The lower concordance rate for IDDM in HLA-identical siblings than in
monozygotic twins indicates that genes other than the HLA also influence the
genetic predisposition to IDDM. Before the first genome scans, two susceptibility
loci affecting the occurrence of IDDM were known: in addition to the MHC on
chromosome 6p21, the insulin gene region on chromosome 11p15 was identified
as an IDDM risk gene in case-control association studies (Julier et al. 1991, Bain
et al. 1992). The first results of genome-wide mapping using microsatellite
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markers displaying a high degree of polymorphism were published in 1994
(Davies et al. 1994, Hashimoto et al. 1994). These results confirmed that the
HLA region, called IDDM1, is the major locus conferring IDDM susceptibility.
The contribution of the insulin gene region, IDDM2, could also be confirmed. In
addition to IDDM1 and IDDM2, 18 other loci showed positive evidence of
linkage to the disease, but not all of them at a statistically significant level
(Davies et al. 1994). Currently at least 13 chromosomal locations have been
shown to have evidence of linkage to IDDM, although they contribute only to a
minor degree to the genetic risk for IDDM (reviewed in Schranz and Lernmark
1998). IDDM1 and IDDM2 have been estimated to contribute to about 40% and
10%, respectively, of familial clustering of IDDM.
2.3 IDDM in APECED patients
Autoimmune type of IDDM is also associated with the systemic autoimmune
disease autoimmune polyendocrinopathy - candidiasis - ectodermal dystrophy
(APECED). APECED is an autosomal recessive disease characterized by chronic
mucocutaneous candidiasis, ectodermal dystrophy and multiple endocrinopathies,
including in most cases hypoparathyroidism and primary adrenocortical failure
(Ahonen et al. 1990). The phenotype of the disease varies widely. It usually
manifests in childhood but new disease components may develop throughout life.
A defect in a novel gene at chromosome 21q22.3, AIRE, has recently been
identified in patients with APECED (The Finnish-German APECED Consortium
1997, Nagamine et al. 1997). The encoded protein is likely to be a transcription
factor, which apparently plays a role in the regulation of immune responses in
APECED. In a large series of patients with APECED the prevalence of IDDM
was 12% (Ahonen et al. 1990). However, autoimmunity against islet cell antigens
is more frequent (Tuomi et al. 1996); antibodies against an IDDM-associated islet
cell antigen, GAD, were present in 41% of patients without clinical IDDM
(Tuomi et al. 1996). In patients with APECED neither clinical IDDM nor GAD
antibody positivity were associated with the HLA DQB1 risk alleles for IDDM
suggesting that in these patients the manifestation of IDDM may be regulated by
factors other than HLA class II antigens (Tuomi et al. 1996). Thus the IDDM of
APECED has characteristics different from the common IDDM.
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2.4 Environmental factors
2.4.1 General aspects
Environmental risk factors may trigger an autoimmune process leading to β-cell
destruction and overt IDDM in genetically susceptible individuals (Nerup and
Lernmark 1981). Several lines of evidence support the major role for
environmental factors in the etiology of IDDM. For example, studies in
monozygotic twins indicate a 30-65% concordance rate for IDDM (Olmos et al.
1988, Kumar et al. 1993). Also, the geographic variation in the incidence of
IDDM is the largest for any chronic non-communicable disease with a genetic
base (Diabetes Epidemiology Research International Group 1988). Some of this
variation may be due to differences in genetic susceptibility, but observations
from HLA studies make it unlikely that the 10-fold difference in IDDM incidence
between different populations in Europe could be exclusively due to genetic
differences (Drash 1990). Further, the incidence of IDDM has shown a
conspicuous increase during recent decades particularly in Europe (Bingley and
Gale 1989). In Finland the annual incidence has been risen from 13/100,000 in
the age group below 15 years in 1953 (Somersalo 1955) to 36/100,000 in the
early 1990s (Tuomilehto et al. 1995). Final support for the role of environmental
factors comes from reports of rapid temporal changes in the incidence of IDDM
in populations who have migrated to an area where the incidence is higher or
lower (Bodansky et al. 1992, Bruno et al. 1996).
In the search for the risk factors that may initiate or accelerate the
autoimmune process leading to IDDM, epidemiological research in particular has
made an important contribution (Dahlquist 1991). In addition to epidemiological
studies, studies on experimental animals have provided abundant examples of the
diabetogenic effects of several factors affecting the pancreatic β-cells either via
the autoimmune mechanism or directly.
2.4.2 Dietary factors
The first reports on the possible effect of dietary components to the incidence of
IDDM are from the early 1980’s. Helgason and Jonasson (1981) proposed that N-
nitroso-compounds in parents’ diets could be an etiological risk factor for IDDM
in the offspring. Since then there have been an accumulating number of studies
on the possible role of cow’s milk (CM) proteins in the etiopathogenesis of
IDDM. Also, plant proteins, nitrates, nitrites and several other dietary factors
have been associated with the etiology of IDDM.
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2.4.2.1 Cow’s milk
The first reports on the role of CM proteins in the pathogenesis of IDDM are
from the middle 1980’s. An anecdotal epidemiological report on lower incidence
of IDDM in Polynesia, where protein content is low in diet, and an abrupt
increase in the incidence of IDDM when Polynesians migrated to New Zealand,
led Elliott and Martin to study the effects of dietary proteins on the occurrence of
IDDM in BB rat (Elliott and Martin 1984). They found that in a BB rat colony,
replacement of CM proteins in chow with amino acids reduced diabetes incidence
from 50% to 15%, and supplementation with skim milk powder again restored
the incidence to 52%. Later it was confirmed that the critical time for the
exposure to CM proteins in BB rat was the weaning period (Daneman et al.
1987), and there have been several reports on the diabetogenic effect of CM
proteins both in BB rats (Scott et al. 1985, Daneman et al. 1987, Atkinson et al.
1988, Hoorfar et al. 1991) and in NOD mice (Elliott et al. 1988, Coleman et al.
1990, Elliott 1995, Reddy et al. 1995).
In man, Borch-Johnsen et al. (1984) were the first to report an inverse
correlation between the prevalence of breast-feeding and incidence rates of
IDDM between 1940 and 1980 in Scandinavia. Since then there have been
several reports demonstrating an inverse association between the duration of
breast-feeding and the risk for IDDM, and a few studies showing no association
and also a minority of studies showing a positive association (reviewed in
Åkerblom and Knip 1998). Two meta-analyses including the results of a series of
case-control studies have shown a relationship between IDDM and a short
duration of breast-feeding, and between an early exposure to CM proteins
(Gerstein 1994, Norris and Scott 1996). In subjects at genetically high risk for
IDDM an even stronger relationship between IDDM and early exposure to CM
proteins (Kostraba et al. 1993), or short duration of breast feeding (Perez-Bravo
et al. 1996) has been demonstrated.
The possible association between the consumption of dairy products later
in life and incidence of IDDM has also been suggested. Three studies have
reported a positive correlation between the incidence of IDDM and CM
consumption at population level (Scott 1990, Dahl-Jorgensen et al. 1991, Fava et
al. 1994). Two case-control studies on the consumption of CM in childhood and
risk for IDDM have been controversial (Dahlquist et al. 1990, Verge et al. 1994).
In Finland no differences were seen in current milk consumption between
diabetic and control children (Virtanen et al. 1994c), but a high milk consumption
in childhood (≥ 3 glasses daily) was associated with more frequent emergence of
IDDM associated autoantibodies than low consumption (< 3 glasses daily) in
siblings of diabetic children (Virtanen et al. 1998).
Savilahti et al. (1988) were the first to report increased levels of IgA class
antibodies to CM and both IgA and IgG class antibodies to CM β-lactoglobulin
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(BLG) in patients with IDDM. Since then there have been several reports on
enhanced humoral immunity to bovine serum albumin (BSA), BLG or CM in
patients with IDDM, and also a couple of studies showing no increase in antibody
levels against CM proteins (reviewed in Åkerblom and Knip 1998). Enhanced
humoral immunity to BSA in patients with newly diagnosed IDDM (Karjalainen
et al. 1992) received probably the most attention, because of the reported cross-
reactivity between a 17 amino acid BSA peptide (ABBOS) and an islet cell
antigen p69 (Pietropaolo et al. 1993, Miyazaki et al. 1995).
Since T cells are thought to have a central role in the pathogenesis of
IDDM, studies on the existence of cellular immunity to CM proteins have been of
great interest. Karjalainen et al. (1993) reported enhanced T-cell reactivity to
BSA in patients with IDDM, but this finding was not confirmed by another group
(Atkinson et al. 1993). Since then there have been two studies in humans showing
enhanced T cell reactivity to BSA and ABBOS in patients with IDDM (Cheung
et al. 1994, Miyazaki et al. 1995), and in at least one study no difference was seen
in T cell reactivity to BSA between the patients with IDDM and healthy controls
(Cavallo et al. 1996), leaving the issue of T cell reactivity to BSA controversial.
T cell reactivity to CM β-casein was recently reported in 51% of patients
with IDDM, and in only 2.7% of healthy people (Cavallo et al. 1996), and in a
later study T cell reactivity to β-casein was shown to be elevated in but not
specific for individuals with IDDM (Ellis et al. 1998a). Cavallo et al. described
several sequence homologies between bovine β-casein and molecules expressed
in β-cells. Especially they mentioned the five amino acid sequence in position 63-
67 of β-casein corresponding to one of the regions of variation between bovine
and human β-casein identical to the residues 415-419 of the β-cell specific
glucose transporter GLUT-2. Thus it could be suggested that molecular mimicry
may be a possible mechanism for maintaining autoimmunity. It should be
emphasized that sequence similarities are frequently identified in database. To
evaluate their biological relevance it will be important to test directly the possible
cross-reactivity of T cells to the peptides in question, and study the ability of the
cross-reactive T cell lines to transfer disease in experimental animals.
A couple of hypotheses of mechanisms possibly explaining the connection
of β-cell destruction and CM protein(s) have been proposed. The BSA hypothesis
(Glerum et al. 1989, Martin et al. 1991) proposes that both in humans and in
animal models for IDDM, CM protein ingestion results in the leakage of these
proteins or fragments of them to circulation due to immaturity of the gut in
neonates. In this model CM exposure leads to immunization to BSA and further
to autoimmunity against β-cells due to cross-reactivity between ICA69 and BSA,
which has been demonstrated both at humoral (Pietropaolo et al. 1993) and
cellular (Miyazaki et al. 1995) level. The BSA hypothesis was further supported
by the finding that the ABBOS epitope was incompletely eliminated when raising
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the pH of the pepsin-catalyzed hydrolysis from 2.0 to 4.0, i.e. under simulated
gastrointestinal conditions of infants (Alting et al. 1997). Elliott et al. have
proposed a model in which β-casein peptides could act as an ”adjuvant” to
macrophages involved in killing β-cells (Elliott et al. 1992). As discussed in the
previous paragraph, Cavallo et al. demonstrated an enhanced cellular reactivity to
β-casein in patients with IDDM and pointed out a sequence similarity between β-
casein and a β-cell antigen GLUT-2 (Cavallo et al. 1996). Recently, Vaarala et al.
(1998 and 1999) proposed that immunization to bovine insulin taken orally in
native CM could break the tolerance to human insulin due to a defect in the gut
immune system.
2.4.2.2 Wheat gluten
Wheat gluten is another dietary factor associated with the risk of diabetes in
diabetes-prone BB rat and in NOD mice (Elliott and Martin 1984, Scott et al.
1988, Hoorfar et al. 1993, Scott et al. 1996). Hoorfar et al. (1993) reported that in
NOD mice wheat flour as the only protein source resulted in the highest
incidence of diabetes among single-protein diets. In addition to the data on
experimental animals, there has been a report on enhanced humoral immune
response to gliadin in patients with IDDM: Catassi et al. (1987) reported
increased antigliadin antibody (AGA) levels at the time of diagnosis in IDDM
patients without villous atrophy in jejunal biopsy; the antibody titers later
decreased gradually. Other groups have reported controversial findings of the
humoral immune responsiveness against gliadin at the diagnosis of IDDM
(Savilahti et al. 1988, Barera et al. 1991). The increased prevalence of celiac
disease in children with IDDM has been reported in several studies (Mäki et al.
1984, Savilahti et al. 1986), and in adult patients with IDDM the prevalence of
celiac disease may be even higher (Collin and Mäki 1994).
2.4.2.3 Others
Among various other dietary exposures that have been associated with increased
risk for IDDM, dietary nitrates and nitrites deserve attention. Nitrate is a naturally
occurring compound in vegetables, whereas both nitrate and nitrite are used as
food additives in the processing of meat products because of their antimicrobial
action and their ability to provide color and taste. Nitrite, and indirectly nitrates,
can be transformed in the gut to N-nitroso compounds, which are structurally
related to streptozotocin. The possibility that N-nitroso compounds could have a
role in the development of IDDM was mentioned already in the 1970’s
(Gunnarsson et al. 1974). In humans a positive relationship between the
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consumption of smoked and cured mutton containing high amounts of N-nitroso
compounds by parents near the conception of the child and the incidence of
IDDM in male progeny was suggested in 1981 (Helgason and Jonasson 1981).
Since then there have been several reports supporting that dietary nitrites and/or
nitrates are associated with an increased risk for IDDM (Dahlquist et al. 1990,
Kostraba et al. 1992, Virtanen et al. 1994a, Parslow et al. 1997).
Coffee and tea consumption (Virtanen et al. 1994b) as well as a high
consumption frequency of carbohydrates or protein have been associated with an
increased risk for human IDDM (Dahlquist et al. 1990). In addition there are
some anecdotal reports on other dietary components associated with IDDM in
animal experiments (Coleman et al. 1990).
2.4.3 Viruses
Common viral infections have long been postulated to participate in the
pathogenesis of IDDM (Szopa et al. 1993). Several studies have been published
showing a seasonal variation in IDDM incidence, a temporal association between
viral infections and the diagnosis of IDDM, the presence of virus-specific
antibodies at diagnosis and the observations that certain viruses are capable of
inducing diabetes in experimental animals. Viruses may act by at least two
possible mechanisms: either by a direct cytolytic effect on β-cells, or by
triggering an autoimmune process leading to β-cell destruction (Yoon 1995).
Although many viruses have been linked to IDDM, increasing evidence has
emerged in recent years for the role of enteroviruses, particularly
coxsackieviruses of group B (CVBs). Other candidate viruses include mumps
virus, rubella virus, cytomegalovirus (CMV) and retroviruses.
2.4.3.1 Enteroviruses
The connection of enteroviruses, coxsackie B viruses in particular, to the etiology
of IDDM is based on a large body of indirect evidence. A seasonal variation in
IDDM similar to the epidemiology of coxsackieviruses of group B (CVBs) was
first described by Gamble and Taylor (1969). Elevated levels of antibodies to
CVBs have been found in patients with newly diagnosed IDDM in some (Barrett-
Connor 1985, Banatvala 1987), but not in all serological case-control studies
(Palmer et al. 1982, Orchard et al. 1983). According to a prospective study by
Hyöty et al. (1995) enterovirus infections were more common in prediabetic
subjects than in healthy children several years before the diagnosis of IDDM, and
infections were temporally associated with increases in IDDM related
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autoantibodies (Hiltunen et al. 1997). In addition, exposure to enterovirus
infection in utero detected as elevated levels of antibodies to enteroviruses in
pregnant mothers has been shown to increase the risk for IDDM in the offspring
(Dahlquist et al. 1995, Hyöty et al. 1995).
Recently, enteroviral RNA sequences have been detected more frequently
in the sera of newly diagnosed IDDM patients than in healthy control subjects
(Clements et al. 1995, Andreoletti et al. 1997). On the other hand, in a study by
Foulis et al. enteroviral RNA was not detectable in 29 pancreases from patients
with IDDM at the time of diagnosis (Foulis et al. 1997). In vitro CVBs can infect
human beta cells in culture, resulting in decreased insulin secretion and over-
expression of HLA class I antigens (Szopa et al. 1993). CVBs have been isolated
from patients with newly diagnosed IDDM, and in two cases the isolated strain of
CVB has been shown to be diabetogenic in an animal model (Yoon et al. 1979,
Champsaur et al. 1980).
Studies on cellular immunity to CVBs in patients with IDDM are limited
to only one paper by Jones and Crosby (1996) examining T cell proliferation to
virus proteins which demonstrate sequence similarity to GAD. Antigens were in
the form of lysates from virus-infected cell lines. The authors reported a higher
magnitude and frequency of T cell proliferative response to CVBs and adenovirus
in patients with newly diagnosed IDDM. The frequency of positive response to
the CVBs was also significantly higher in IDDM subjects expressing the
DRB1*04 HLA haplotype than the DRB1*03 haplotype (Jones and Crosby
1996).
One possible mechanism by which CVBs may induce IDDM is based on
the reported similarity between the non-structural protein 2C of CVB4 and GAD
(Kaufman et al. 1992). The molecular mimicry theory was supported by the
evidence of cross-reactive anti-CVB4 responses to GAD, the identification of this
shared peptide as a major GAD determinant in IDDM patients, and the
inducibility of the cross-reactive response in peptide immunized mice (Kaufman
et al. 1992, Atkinson et al. 1994, Tian et al. 1994). However, Horwitz et al.
(1998) reported controversial evidence suggesting that diabetes induced by CVB
is a direct result of local infection leading to tissue damage and the release of
sequestered islet antigen resulting in the re-stimulation of resting autoreactive T
cells.
2.4.3.2 Others
Other candidate viruses associated with the risk for IDDM include mumps virus,
rubella virus, cytomegalovirus and retroviruses (Yoon 1995). In epidemiological
studies the number of diabetic cases increased significantly 2-4 years after an
unusually sharp epidemic of mumps (Hyöty et al. 1988), and a plateau in the
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earlier increasing incidence of IDDM was observed in Finland 6 years after
starting the mumps-measles-rubella vaccination (Hyöty et al. 1993). The plateau,
however, subsequently disappeared and the incidence has in recent years
increased further. Probably the most convincing evidence of the role of viruses in
the development of IDDM comes from studies showing that diabetes is found in
up to 20% of patients with congenital rubella syndrome, with a latent period of 5-
20 years (Menser et al. 1978). Quite recently a structural homology between a
dominant epitope of IA-2 and a major immunogenic protein of human rotavirus
was reported (Honeyman et al. 1998) suggesting that rotavirus may be involved
in the development or maintenance of autoimmunity against pancreatic β-cells.
Conrad et al. (1997) described the isolation of previously unknown
endogenous HERV-K retroviral genome. Transcrips derived from this genome
were detectable in the plasma of 10/10 newly diagnosed IDDM patients, but not
from 10 non-related control subjects. The authors proposed that β-cell destruction
is caused by systemic activation of autoreactive T cells due to the expression of a
superantigen encoded by an endogenous retrovirus on antigen-presenting cells
(Conrad et al. 1997). Recently, these findings could not be confirmed be several
independent groups (Lan et al. 1998, Löwer et al. 1998, Murphy et al. 1998).
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3. AIMS OF THE STUDY
The objectives of this work were:
1. to assess the occurrence of cellular immunity to environmental antigens (CM
BLG, wheat gluten, CVB4) in patients with newly diagnosed IDDM and in
control children,
2. to characterize cellular immunity to an islet cell autoantigen (GAD) in
patients with newly diagnosed IDDM, patients with APECED and in control
subjects, and to evaluate the association between cellular immunity to GAD
and CVB4 in patients with IDDM and in control subjects,
3. to investigate the association between HLA DQB1 risk alleles for IDDM and
the observed T cell responses in patients with IDDM, patients with APECED
and in control subjects,
4. to explore the potential association between clinical IDDM and T-cell
reactivity to GAD in patients with APECED, and
5. to investigate the expression of gut-specific homing receptor α4β7-integrin on
GAD-reactive lymphocytes.
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4. SUBJECTS AND METHODS
4.1 Subjects
The summary of subjects included in this research is shown in table 1. Subjects in
papers I, II, III, and V comprised mainly consecutive patients with newly
diagnosed IDDM admitted to the Hospital for Children and Adolescents,
University of Helsinki, Aurora Hospital, Helsinki or Jorvi Hospital, Espoo for
initial treatment of IDDM, and unrelated control children without signs of acute
infections or autoimmune diseases undergoing minor elective surgery at the
Hospital for Children and Adolescents, University of Helsinki. Patients with
newly diagnosed IDDM and control subjects were partially shared between the
various investigations. All patients with newly diagnosed IDDM were studied
within 1 month (papers I and II) or 2 months (paper III) after the diagnosis. The
patients and control subjects were always tested in parallel using fresh blood
samples. The blood samples were drawn after informed consent of the patients,
patients’ parents or control subjects. The study plans were approved by the
hospitals’ ethics committees.
Paper II included also patients with a duration of IDDM of more than 2
years attending the diabetes clinics of the Hospital for Children and Adolescents,
University of Helsinki. These patients were selected randomly in connection with
their clinic visits. Mean (range) duration of IDDM was 6.1 (2.2 - 14.1) years in
these patients. In paper II celiac disease (CD) was excluded in all study subjects
by using positive endomysium antibodies, which were found to have 100%
specificity and 94% sensitivity in the same laboratory (Kolho and Savilahti 1997),
as a criterion for CD.
In paper III the number of patients tested with different antigen
preparations varies because all antigen preparations were not always available
during the whole study period, or there were not enough lymphocytes to perform
all cell cultures planned.
In paper IV all 44 available Finnish APECED patients were studied. They
all had at least one of the following disease components: hypoparathyroidism and
primary adrenocortical failure, and all had chronic mucocutaneous candidiasis.
Fourty-one of the 44 patients (93%) had hypoparathyroidism, 34 (77%) had
primary adrenal failure, 18 (41%) had primary gonadal failure, and two (4%) had
hypothyroidism. Eight (18%) of the patients had clinical IDDM. The diagnostic
criteria of each disease component have been described elsewhere (Ahonen et al.
1990, Tuomi et al. 1996). The mean (median; range) duration of IDDM was 11.2
yr (11.2; 4.6 - 19.6). All but one of the patients were under 25 yr at the time of
IDDM diagnosis (range 4.1 - 45.3 yr). Mean (median; range) dose of insulin in
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the patients was 0.68 (0.68; 0.42-0.95) IU/kg/day. The diagnosis was based on
classical manifestations of IDDM in seven of eight patients. The eighth patient
was symptomless at the diagnosis of diabetes at 45 years of age. Three years after
diagnosis his insulin dose was 0.23 IU/kg/day and 4.5 years after the diagnosis (at
the time of the present study) 0.42 IU/kg/day. Fourteen nondiabetic patients
underwent an IVGTT. During a 12 - month period after performing T-cell assays
three patients developed IDDM and are thus considered prediabetics. A control
group consisted of laboratory personnel and students without clinical
manifestation of autoimmune diseases. T-cell assays in patients and control
subjects were performed with fresh blood samples collected between June 1995-
February 1996 when the patients visited the out-patient clinic of the Hospital for
Children and Adolescents, University of Helsinki.
In paper V patients with IDDM, the prediabetic subject and APECED
patients were selected for the study because of their cellular immunity to GAD
(stimulation index above three in T cell proliferation assay).
Table 1. Summary of subjects included in this research.
Paper Subjects Number (f/m) Mean age, year (range)
I Children with newly diagnosed IDDM
Control children
40 (16/24)
32 (15/17)
7.1 (1-17)
9.1 (1-17)
II Children with newly diagnosed IDDM
Children with IDDM > 2 years
Control children
29 (14/15)
39 (16/23)
37 (16/21)
8.2 (1.0-17.1)
12.7 (4.4-19.3)
9.8 (1.1-17.0)
III Children with newly diagnosed IDDM
Control children
82 (43/39)
63 (26/37)
8.3 (0.9-17.1)
8.9 (1.2-17.6)
IV Patients with APECED
          with IDDM
          without IDDM1
Control subjects
44 (27/17)
8 (2/6)
36 (25/11)
28 (23/5)
29.7 (10.1-57.8)
31.6 (21.3-49.9)
28.0 (10.1-57.8)
32.8 (23-58)
V Patients with newly diagnosed IDDM
A prediabetic subject2
Patients with APECED
Control subjects
6 (1/5)
1 (0/1)
3 (3/0)
3 (3/0)
9.6 (3.8-15.3)
6.3
33.2 (29.4-37.9)
30.6 (28.6-32.9)
1Three initially non-diabetic APECED patients aged 12.3 years (a male subject), 34.9
and 42.8 years (female subjects) contracted IDDM during a 12 - month period after
performing T-cell assays.
2A first degree relative of an IDDM patient with positive ICA
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4.2 Antigens
CM derived antigens and ovalbumin. Bovine serum albumin, β-lactoglobulin and
α-casein, as well as ovalbumin (OVA) were all obtained from Sigma (St. Louis,
MO; catalog numbers A2058, L0130, C6780, and A5378, respectively).
Wheat gluten. The starting material for the antigen was commercial crude
wheat gluten (Sigma). Enzymatic hydrolysis of antigen was performed as
described by Frazer et al. (1959) and fraction III was used as gluten antigen in
this study.
GAD65. A baculovirus expression vector pVL 1393 (Invitrogen, San
Diego, CA) carrying the human GAD65 gene was used to infect Spodoptera
frugiperda (ATCC, Rockville, MD) cells in suspension cultures as previously
described (Moody et al. 1995). The cell pellets from cultures were stored at -70oC
48-54 h after infection. For GAD65 purification the cells were lysed by
sonicating. Lysis buffer (200 mM NaHCO3 containing 1 mM pyridoxal
phosphate, 1 mM 2-aminoethyl isothiouronium bromide and 1 mM
phenylmethylsulfonyl fluoride) and supernatant were cleared from unsolubilized
material by centrifugation (12,000 rpm for 10 min at 4oC). Immunoaffinity
purification was performed using monoclonal antibody GAD-6 (Developmental
Studies Hybridoma Bank, Iowa, IA). The purified antibody was coupled to CnBr-
activated sepharose 4B (Pharmacia, Uppsala, Sweden). Supernatant from infected
cells and antibody resin were mixed, and the antibody-antigen reaction was
carried out at pH 9.2 for at least 16 h by rotating the mixture at 4oC. The resin
was washed twice and transferred to a column that was developed at pH 2.7. The
effluent was neutralized, and the precipitated GAD65 pelleted and solubilized in
100 mM/l NaHCO3, pH 9.2. The purity of the preparates was confirmed by SDS-
PAGE followed by staining with Coomassie brilliant blue and Western blot
analysis with GAD-6 or polyclonal rabbit anti-GAD65 as primary and
horseradish peroxidase-conjugates as secondary antibodies, and ECL-reagent
(Amersham, Buckinghamshire, England) to visualize the result on X-ray film.
The endotoxin content of the antigen preparations was tested by Limulus test, and
it was below the detection level of the test (0.062 EU/ml corresponding to about 2
pg/ml of endotoxin) in all the antigen preparations used.
In a subgroup of ten subjects, acetylcholinesterase (AChE) expressed in
the baculovirus expression system and purified by immunoaffinity column using
specific antibodies to AChE was used as a control antigen. As another control for
possible contamination of Sf9 cell lysate in GAD we tested T cell reactivity to
Sf9 cell lysate infected with baculovirus in a series of 16 individuals at a
concentration of 0.1 µg/ml and in 20 individuals at a concentration 1.0 µg/ml.
Coxsackievirus B4 strain J.V.B. (CVB4) and poliovirus type 1/Sabin
(PV1) were grown in GMK and Hep-2 cells, respectively. GMK is a continuous
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cell line of African green monkey kidney origin and Hep-2 (Cincinnati) is a
human epidermoid cancer cell line. Crude virus preparations were cleared from
cell debris by low speed centrifugation and purified further on sucrose gradients
as described earlier (Abraham and Colonno 1984).
Tetanus toxoid (TT) (National Public Health Institute, Helsinki, Finland)
served as the control antigen.
4.3 T cell proliferation assay
Peripheral blood mononuclear cells (PBMCs) were separated by Ficoll-Hypaque
(Pharmacia) density centrifugation and washed three times in phosphate buffered
saline (Orion Diagnostica, Espoo, Finland). Cells (1 x 105) diluted in RPMI 1640
(Gibco, Paisley, Scotland) containing 5% heat inactivated pooled human AB+
serum (Finnish Red Cross Blood Transfusion Service, Helsinki, Finland) and 2
mM L-glutamine were cultured in U-bottomed microwell plates (Nunc, Roskilde,
Denmark) in 200 µl volume per well. Four replicates for each antigen and eight
replicates for the baseline-value (cells with medium alone) were included in our
T cell assay. Antigen concentrations were 2, 20, 200 µg/ml for CM proteins and
OVA, 40 and 400 µg/ml for wheat gluten, 0.1 and 1 µg/ml for CVB4 and PV1, 1
and 10 µg/ml for GAD, and 10 µg/ml for TT. After 5 days of incubation, 1 µCi
tritiated thymidine (specific activity 25 Ci/mM; Amersham) was added to each
well for 16-18 hours of incubation. The cultures were harvested automatically,
and thymidine incorporation was measured by a Microbeta® counter (Wallac Ltd,
Turku, Finland). Proliferation was expressed as a stimulation index (SI) = median
counts per minute (cpm) incorporated in the presence of antigen divided by
median cpm incorporated in the absence of antigen.
Inhibition of the proliferation of PBMCs to wheat gluten or to BLG was
studied by adding monoclonal anti-HLA-DR antibodies (Becton Dickinson, San
Jose, CA) to the cultures at the beginning of the proliferation assay. The
antibodies were dialyzed to remove preservatives and used at final concentrations
of 1/500 and 1/100.
4.4 Depletion of α4β7-expressing lymphocyte population from the PBMCs
The PBMC population was isolated by Ficoll-Hypaque (Pharmacia) density
centrifugation. The PBMCs were suspended at a cell concentration of 8 x 106
cells/ml to the culture medium, which was RPMI-1640 (Gibco) containing 5%
pooled human AB+ serum (Finnish Red Cross Blood Transfusion Service) and 2
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mM/ml L-glutamine. Monoclonal antibodies to α4β7-integrin (ACT-1)
(Lazarovits et al. 1984) were added to the cell suspension, with a final ratio of 0.5
µg/ml of protein per 106 cells. After a 30-min incubation, the cells were washed,
and magnetic beads coated with monoclonal antibodies to mouse
immunoglobulin (Dynal, Oslo, Norway) were added. Lymphocytes bound to the
magnetic particles were separated in the magnetic particle concentrator (Dynal
MPC-E), and both the supernatant corresponding to the α4β7-depleted population
of PBMC (α4β7low) and the pellet containing the cell population corresponding to
the α4β7-high expression cells (α4β7high) was collected.
4.5 Flow-cytometry analysis of lymphocyte surface antigens
For cell staining, Ficoll-separated PBMCs and α4β7-depleted PBMCs were
preincubated in goat IgG to block nonspecific antibody binding. For two-color
analysis, cells were consequtively incubated with ACT-1 (0.3 µg/105 cell), goat
anti-mouse Fab conjugated to fluorescein isothiocyanate (FITC), normal mouse
IgG, and phycoerythrin (PE)-conjugated monoclonal antibodies against CD4 or
CD8 (Becton Dickinson). Incubations were performed at room temperature for 15
min and cells were washed after incubation with both ACT-1 and PE-conjugated
antibodies. Lymphocyte gate was set by using CD14/CD45 antibodies
(Leukogate, Becton Dickinson).
4.6 ELISA for IFN-γ
96-well Maxisorb plates (Nunc) were coated with monoclonal anti-human IFN-γ
antibody (M-700A, Endogen, Cambridge, MA) at a concentration of 2 µg/ml (50
µl/well). The plates were incubated overnight at +4oC. After washing with PBS-
Tween, the plates were blocked with 1% BSA in PBS for 30 min at +20o C.
Dilutions of recombinant human IFN-γ (19751N, Pharmingen, San Diego, USA)
were used to create a standard curve. Supernatant samples (100 µl/well) and
standards were incubated for 2 h at +20oC. After washing with PBS-0.05%
Tween, biotinylated anti-human IFN-γ monoclonal antibody (M-701, Endogen,
Boston, MA) was added at a concentration of 0.5 µg/ml (50 µl/well) and the
plates were incubated for 1 h 30 min at +20º C. After washing with PBS-Tween,
streptavidin-alkaline phosphatase complex (Zymed, San Francisco, CA) was
added for 30 min incubation at +20º C. After that p-nitrophenyl phosphate
(Medix, Kauniainen, Finland) was used to develop the color read at 405 nm. The
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concentration of IFN-γ detected in the wells cultured without antigen was
subtracted from the concentration of IFN-γ detected in the antigen-stimulated
wells. The detection level of the assay was 50 pg/ml. The intra- and interassay
coefficients of variation were 8.7% and 13.8%, respectively.
4.7 Antibody assays
4.7.1 IgG- and IgA-class antibodies to BLG
IgG- and IgA-class antibodies to BLG were detected by enzyme-linked
immunosorbent assays (ELISAs) as previously described (Dahlquist et al. 1992,
Savilahti et al. 1993). The level of antibodies was considered positive when it
was above the detection threshold of the assay (>0.01% of standard serum with
high levels of antibodies against BLG).
4.7.2 Anti-gliadin IgG and IgA antibodies
IgA and IgG class AGA were measured with a solid-phase ELISA (Savilahti et
al. 1983, Kolho and Savilahti 1997). In brief, 75 µl serum samples (diluted 1:200
for IgA-AGA and 1:400 for IgG-AGA) were applied to microtiter plate wells
coated with commercial gliadin suspension (BDH, Poole, England). After
incubation at +37° C overnight the plates were washed, and alkaline-
phosphatase-labeled anti-human IgA or IgG immunoglobulins (Orion
Diagnostica) were added for an additional 1 h incubation at +37° C. After
washing, the substrate (2 mg/ml p-nitrophenyl-phosphate in diethanolamine
buffer) was added and incubated 30 min at +37° C. The end product was
measured photometrically at a 405 nm wavelength. Positive and negative control
and buffer blanks were run in each assay, and the results were obtained from the
standard curve established from three dilutions of a positive reference. The
antibody concentrations are expressed as percentages of the reference. A
percentage ≥ 20% was considered positive; when the cut-off level of 20% was
used for both IgA and IgG tests, the sensitivity and the specificity were highest
for CD (Kolho and Savilahti 1997).
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4.7.3 GAD antibody assay
In paper III antibodies to GAD (GADA) were measured with a radiobinding
assay as earlier described (Savola et al. 1998). The GAD65 protein was produced
by in vitro transcription and translation using the TNT Coupled Reticulocyte
Lysate System (Promega, Madison, WI) in the presence of 35S-methionine
(Amersham). Serum samples were incubated with labeled GAD65, and the
immune complexes were isolated using Protein-A-Sepharose (Pharmacia). The
results were expressed in relative units (RU) based on a standard curve. The limit
for GADA positivity (5.35 RU) was set at the 99th percentile for 373 non-
diabetic Finnish children and adolescents. The disease sensitivity of the GADA
assay was 69% and its specificity 100% based on 140 samples included in the
1995 Multiple Autoantibody Workshop.
In paper IV, GAD antibodies were determined by a radiobinding assay of
Grubin et al. (Grubin et al. 1994) as modified by Falorni et al. (1995). The results
were expressed as an index = (sample cpm - mean cpm of 3 negative standard
sera) / (positive standard serum cpm - mean cpm of three negative standard sera)
x 100. Antibody levels exceeding an index of 5, i.e. mean + 3 SD of Finnish
healthy children (n = 64, mean age 7.9 yrs), blood donors (n = 50), and
nondiabetic adults (n = 182, mean age 55 yrs) were considered positive. All sera
with an antibody index over 40 were titrated to an end-point dilution still giving a
positive index, and the final result was expressed as the end-point result
multiplied by the dilution factor as described earlier (Tuomi et al. 1996). The
antibody testing was performed in the serum samples taken from the patients at
the time of T-cell testing, although some patients overlap with the study of Tuomi
et al. (1996). In the Combined Autoantibody Workshop (Orvieto, Italy, 1995), the
specificity of the assay was 99%, and the sensitivity 75%.
4.7.4 Enterovirus antibody assay
IgG class antibodies against CVB4 (CVB4-Ab) were analyzed using purified
CVB4 viruses as antigen in the enzyme immunoassay (EIA) protocol described
earlier (Hyöty et al. 1995, Hiltunen et al. 1997). Purified CVB4 viruses were first
heated for 30 min at 56oC to expose heterotopic antigen determinants common
for various enteroviruses.
4.7.5 TT antibody assay
Antibodies to TT were measured by ELISA. Maxisorb (Nunc) plates were coated
overnight at +4°C with TT at a concentration of 1 µg/ml. After washing with
0.05% Tween-PBS, residual coating was performed with 1% human serum
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albumin (HSA)-PBS. Plasma samples were diluted 1:800 in 0.2% HSA 0.05%
Tween-PBS and incubated for 2 h at room temperature. Alkaline phosphatase
conjugated rabbit anti-human IgG (Fc) (Jackson Immunoresearch, West Grove,
PA) was diluted 1:3,000 in 0.2% HSA 0.05% Tween-PBS and incubated for 90
min at room temperature. After washing with 0.05% Tween-PBS, P-nitrophenyl
phosphate (Sigma) was added, and after a 30 min incubation the absorbance was
read at 405 nm. Results were expressed as optical density (OD).
4.8 HLA DQ typing
In papers I, II and III HLA DQB1 typing was performed by a technique
developed for screening of IDDM susceptibility based on the presence of HLA
DQB1 alleles associated with a significant risk for (HLA DQB1*0302,*02) or
with protection against (HLA DQB1*0602/0603,*0301) the disease (Sjöroos et
al. 1995). The HLA DQB1 gene segment of interest was amplified by a
biotinylated 3’ primer, and the amplification product was bound by streptavidin-
coated microtiter plate wells. The hybridization of various lanthanide-labeled,
short allele-specific oligonucleotide probes was measured by means of time-
resolved fluorometry. To analyze the effect of HLA genotype, the patients and
controls were divided according to the presence of the DQ risk alleles in their
genotypes. In papers I and II, the groups compared were those with both risk
haplotypes (DQB1*0302/DQB1*0201), those with only one of the risk
haplotypes (DQB1*0302/x and DQB1*0201/x) as well as those without any risk
haplotypes (DQx/x). In paper III, HLA-DQB1*02 positive samples were further
tested for the presence of DQA1*05 or DQA1*0201 alleles (Sjöroos et al. 1998),
and the HLA groups were: DQA1*05-DQB1*02/DQB1*0302, DQB1*0302/x,
DQA1*05-DQB1*02/x and DQx/x.
In paper IV HLA DQB1 genotyping was performed by dot-blot
hybridization of PCR-amplified DNA with digoxigenin-labeled oligonucleotide
probes according to the protocols of the 11th International Histocompatibility
Workshop (Tuomi et al. 1996, Kimura and Sasazuki 1991). In paper IV only the
data on the IDDM susceptibility alleles DQB1*0201 and 0302 are given, other
alleles are given as x.
4.9 Statistical analysis
In the lymphocyte stimulation experiments the differences in SIs between patients
and control subjects were analyzed by the nonparametric Mann-Whitney U test,
Kruskal Wallis test or Fisher’s exact test. Spearman’s correlation was used to
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analyse the correlations between antibody and T cell responses, and T cell
responses to different antigens.
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5. RESULTS AND DISCUSSION
5.1 Cellular immunity to dietary proteins (I, II)
5.1.1 T-cell response to CM proteins and OVA (I)
The median SIs to BLG at the concentration of 200 µg/ml for the patients and the
control subjects differed significantly (3.3 versus 1.5; p=0.003 in Mann Whitney
U test). In contrast, proliferation of PBMCs to other CM proteins, such as BSA
and α-casein, did not differ between the groups (p=0.49 and 0.60, respectively).
The proliferation response to BSA was low for both the patients and the control
subjects (median SIs 1.0 for both groups at the concentration of 200 µg/ml). The
median SIs to OVA (200 µg/ml) for the patients and control subjects did not
differ significantly (2.1 vs. 1.8 respectively). We found a positive proliferation
response of PBMCs to BLG (SI>3) in 22 of 40 (55%) children with newly
diagnosed IDDM, but only in seven of 32 (22%) non-diabetic children (Chi-
square; p=0.004). The distribution of SIs to BLG in patients with IDDM and
healthy subjects is shown in Figure 1.
The highest SIs were detected at a concentration of 200 µg/ml although in
most cases proliferation was seen already at a concentration of 20 µg/ml. The
median SI to TT was 21 in the control subjects and 16 in the patients, and the
groups did not differ significantly (Mann Whitney U test; p=0.44). The
inhibitionof the proliferation of PBMCs to BLG was studied in two patients with
previously detected positive stimulation index to BLG. In both patients, anti-
HLA-DR antibodies inhibited the proliferation to BLG.
IgG- and IgA-class antibodies to BLG were measured in 37 patients and
31 control subjects. No significant difference was found in the levels of
antibodies to BLG between the groups. Antibodies to BLG were found in control
children mostly without detectable cellular reactivity to BLG (Table 2 in paper I),
suggesting a Th2 type responsiveness. In patients with IDDM this kind of
responsiveness was rare, and cellular reactivity without antibodies was often
seen. This suggests that BLG-reactive T helper cells may be functionally different
in children with IDDM when compared to healthy children.
Enhanced cellular reactivity to BLG in our series of IDDM patients is in
agreement with earlier studies showing augmented humoral immune response to
CM BLG (Savilahti et al. 1988, Dahlquist et al. 1992). Reports on the cellular
reactivity to CM proteins have been rare. Cheung et al. (1994) studied T cell
reactivity to BSA, human and horse serum albumin, and bovine BLG in a serum-
free cell culture medium, and reported an enhanced cellular reactivity to BSA, but
not to other proteins in patients with IDDM. This finding could not be confirmed
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in our patients. In our series proliferation responses to BSA were low in all
subjects studied, which is in accordance with the study by Atkinson et al. (1993).
We have also studied children with CM allergy and have found proliferation
responses to BSA (SI > 3) in some of them (data not shown) in our cell culture
assay. Thus our proliferation assay does detect responses to BSA although
epitopes related to CM allergy may differ from those in IDDM. However,
methodological differences may explain discrepant results between these two
studies, the major difference being the use of a serum-free cell culture medium in
the study by Cheung et al.
Enhanced cellular reactivity to bovine β-casein has been reported in
patients with newly diagnosed IDDM (Cavallo et al. 1996). In the present study
reactivity to β-casein was not studied, but we have later measured reactivity to β-
casein in patients with newly diagnosed IDDM and in control subjects. T cell
reactivity to β-casein was seen often in both groups but there was no difference
between the patients and control subjects (data not shown).
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Figure 1. Proliferation
response to BLG in patients
with newly diagnosed IDDM
and in control subjects.
Stimulation index of 3.0 is
marked as the cutoff level for
positivity and median SI of
each group is shown.
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There are some minor methodological differences between the T cell
proliferation assay used by Cavallo et al. (1996) and our assay (i.e. the use of
autologous serum in the study by Cavallo et al.), which may partly explain the
discrepancy in observed reactivity to β-casein. There was also a difference in the
age of study subjects: the study by Cavallo et al. comprised older patients and
control subjects than our study. Age may be an important determinant for the
presence of immune response to oral antigens and thus the difference in the age
of the study subjects may be a major reason for higher reactivity to BLG in
healthy subjects in our study compared to that in the study by Cavallo et al.
In contrast to the reactivity to BLG, we could not find enhanced cellular
reactivity to α-casein, BSA or OVA in patients with newly diagnosed IDDM. The
immunogenic properties of dietary BLG may differ from those of other dietary
proteins. BLG is a component of whey proteins in CM. It stays soluble at low pH,
is not precipitated in the stomach, and reaches the intestine in an intact form. In
patients with CM allergy, humoral immunity to BLG is also seen in the majority
of cases (Savilahti and Kuitunen 1992).
In earlier studies antibodies to BLG have been reported to be enhanced in
patients with newly diagnosed IDDM (Savilahti et al. 1988, Dahlquist et al. 1992,
Savilahti et al. 1993), but this enhancement was most marked in the youngest
children with IDDM. The mean age of the patients in our study was 7.1 years,
which may explain why no difference was found in BLG antibody levels between
the patients with IDDM and the control subjects in our study.
We did not find any differences in the proliferation responses to BLG
between patients with and without HLA DQB1 risk alleles for IDDM. The
immunization to BLG in patients with IDDM seems to occur irrespective of the
HLA type. This may be due to several immunogenic epitopes in BLG, which may
have binding capacity to different HLA molecules. Although HLA typing was
performed only in a subgroup of patients, it appears that enhanced cellular
reactivity to BLG is not a secondary phenomenon of the excess of specific HLA
types in patients with IDDM, but rather is associated with IDDM as such.
The observed immune responsiveness to BLG in patients with newly
diagnosed IDDM may reflect a defect in the development of immune tolerance to
oral antigens in IDDM. Both humoral and cellular immunity to BLG have been
reported in healthy infants who were exposed to BLG orally in CM formula,
whereas no response was seen in infants who received only casein-hydrolysate
formula (Vaarala et al. 1995). During the follow-up, T cell response to BLG
declined, suggesting the development of oral tolerance in healthy infants.
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5.1.2 T-cell response to wheat gluten (II)
We found a positive proliferation response to gluten in seven of 29 patients with
newly diagnosed IDDM (24.1%), in six of 39 patients with longer duration of
IDDM (15.4%), and in two of 37 nondiabetic control subjects (5.4%) when three
multiples of the median SI in the control subjects (SI>3) was used as a cut-off for
positivity (Figure 2).
Elevated proliferation response to gluten was significantly more frequent
in the patients with newly diagnosed IDDM than in the control subjects (patients
with recent IDDM vs. control subjects: p=0.03; patients with longer duration of
IDDM vs. control subjects: p=0.16; χ2 test). The median SIs to gluten differed
between the three groups (p=0.04; Kruskal-Wallis test). The median SI to gluten
was higher in patients with newly diagnosed IDDM than in control subjects (2.0
vs. 1.5; p=0.03), whereas the median SI for patients with longer duration of the
disease did not differ when compared with the control subjects (1.3 vs. 1.5;
p=0.79 Mann-Whitney U test). The median SI was lower in patients with longer
duration of IDDM when compared with patients with newly diagnosed IDDM
(1.3 vs. 2.0; p=0.03).
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Figure 2. The distribution of stimulation indexes (SI) to gluten in patients with newly
diagnosed IDDM, in patients with longer duration of the disease, and in control subjects.
An SI value of 3.0 was used as the cut-off limit for positive proliferative response. Median
SIs of each group are marked with horizontal lines.
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The inhibition of the proliferation of PBMCs was studied in two patients
with positive SIs to gluten. In both patients, anti-HLA-DR antibodies inhibited
the proliferation to gluten.
We found increased levels of IgA-AGA (≥ 20) in three of 29 patients with
recent IDDM, in two of 33 patients with longer duration of IDDM and in one of
37 control children. Both IgA- and IgG-AGA were increased (≥ 20) in one
patient with newly diagnosed IDDM and in one patient with longer duration of
disease. IgA- and IgG-AGA showed no correlation with the proliferative
response to gluten in IDDM patients or control children. All patients and controls
were negative for anti-endomysium antibodies of IgA class.
HLA-DQB1 typing was performed in a subgroup of 27 patients with
newly diagnosed IDDM, 32 patients with longer duration of IDDM, and 35
control subjects. The positive proliferative response to gluten was not associated
with HLA-DQB1*0302/0201, 0302/x, or 0201/x haplotypes in the patients. In the
control subjects the median SI was higher in individuals with DQB1*0201,x
haplotype than in individuals with none of the risk alleles, 2.5 and 1.2
respectively (p=0.02; Mann-Whitney U test).
T cell responsiveness to gluten was low in our series of patients and
control subjects. There have been reports of both high (Jensen et al. 1995,
Gjertsen et al. 1994b) and low (Sikora et al. 1976, Baker et al. 1995) T cell
responsiveness to gluten in healthy control subjects. One explanation for this
discrepancy could be the wide variation of gluten or gliadin concentrations used
in the different studies. Also, in the generation of gliadin-specific T cell lines,
antigen concentrations have varied widely, from 100 µg/ml to 2.5 mg/ml (Franco
et al. 1994, Gjertsen et al. 1994a). The concentration of 400 µg/ml used in our
study is comparable to the concentration of 600 µg/ml used by Gjertsen et al.
(1994b) who reported the highest responses to gluten or gliadin at concentrations
of 0.6 mg/ml or 2.4 mg/ml. The optimal antigen concentration in T cell
proliferation assays is usually from 0.1 to 100 µg/ml, and thus the concentration
of 400 µg/ml in the present study can be considered high. According to the dose-
response curve, however, a concentration of 400 µg/ml is needed for the
proliferation of T cells.
T cell responsiveness to gluten was enhanced in patients with newly
diagnosed IDDM, but the responses to gluten were low in general. This suggests
that T cell immunity to wheat gluten may not play an important role in the
pathogenesis of human IDDM. Instead, the results support the previous studies
suggesting that immunity to oral proteins is altered in patients with recent IDDM.
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5.2 Cellular immunity to enteroviruses (III)
Median SI to CVB4 was 3.30 in IDDM patients compared to 2.35 in control
subjects (p=0.13; Mann-Whitney U test). An enhanced proliferative response of
PBMCs to CVB4 was found in 20 of the 74 (27%) IDDM patients and in five of
the 48 (10.4%) control children (p=0.04; Fisher’s exact test) when the cut-off for
positivity was three multiples (SI≥7.05) of the median SI in healthy children
(Figure 3). When four multiples of the median (SI≥9.40) was used as the cut-off
point, 16 patients and three controls had an SI above this limit (p=0.02).
There was no difference in the median SIs to PV1 (3.50 in patients with
IDDM compared to 3.55 in control subjects; p=0.9, Mann-Whitney U test). When
three multiples of the median (SI≥10.65) was used as cut-off point, four patients
and none of the controls had an SI above this limit (p=0.3; Fisher’s exact test),
and when the cut-off point was four multiples of the median (SI≥14.20) three of
the patients and none of the controls had an SI above this (p=0.3).
No statistically significant differences were observed in T-cell responses
to CVB4 between patients carrying various HLA DQ risk alleles for IDDM
(p=0.50, Kruskal Wallis test), and the same held true in the control subjects
(p=0.67, Kruskal Wallis test). T-cell responses to CVB4 were analyzed also in
patients and control subjects matched for the same DQ allele. The numbers of
cases in the subgroups of patients and/or control subjects with different HLA
DQB1 genotypes were small, and no statistically significant differences were
seen between the patients and control subjects.
There was no difference CVB-Ab between the patients (n=74) and control
children (n=48). Median CVB-Ab level (range) was 17.5 EIU (0 - 126) in the
IDDM patients and 19.5 EIU (1 - 149) in the control children. The T-cell
responses to CVB4 and CVB-Ab levels did not correlate in the patients with
IDDM (r=0.21; p=0.08), nor in the control children (r=-0.06; p=0.67).
Concerning the results of enhanced T-cell reactivity to an coxsackie B4
antigen in patients with IDDM, our study is in accordance with the report by
Jones and Crosby (1996), who used lysates from virus infected cell lines as an
antigen. In contrast to the purified CVB4 antigen used in the present study, the
cell lysate antigen contains non-structural viral proteins. One of these, the 2C
protein, carries the previously described homology sequence with GAD. Lack of
this homology sequence in our CVB4 antigen suggests that the observed
enhanced reactivity to CVB4 in patients with IDDM does not reflect
autoimmunity to GAD. It is possible that an enhanced cellular reactivity to
coxsackievirus antigens at the time of IDDM diagnosis reflects preceding
enterovirus infections, as indicated by sero-epidemiological studies (Hyöty et al.
1995).
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Figure 3. T-cell proliferation response to CVB4 expressed as stimulation indexes (SI) in
patients with newly diagnosed IDDM and in control children. The cut-off level for
positivity determined as three multiples of median SI in the control subjects is marked
with a horizontal line.
In the present study no difference in the antibodies to CVB4 was seen
between the IDDM patients and control subjects. The result is in accordance with
a previous cross-sectional study in Finland in which no clear association in
antibody levels to CVB4 was seen between the patients with newly diagnosed
IDDM and healthy children (Hyöty et al. 1995). However, in a prospective study
on siblings of IDDM children, sequential enterovirus infections were detected
already years before the IDDM diagnosis in the siblings who developed IDDM
when compared to siblings who remained unaffected (Hyöty et al. 1995). T-cell
responses to recall antigens usually exist for a long time after immunization.
Thus, enhanced T-cell responses to enteroviral antigens (i.e. CVB4) in patients
with IDDM at diagnosis may reflect an excess of preceding enterovirus infections
in these subjects, even if the antibody levels did not differ.
HLA DRB1*04 has been suggested to associate with high T-cell responses
to CVB4 (Bruserud and Thorsby 1985). We could not find a significantly higher
frequency of positive T cell responses or IgG antibody responses to CVB4 in
IDDM patients carrying HLA DQB1*0302 which is in linkage disequilibrium
with the HLA DRB1*04 allele. Our control group, comprising randomly selected
children, can be assumed to have the same distribution of HLA DQ alleles as the
background population, which differs from that of patients with IDDM.
However, in the control subjects with the HLA DQB1*0302 allele the responses
to CVB4 were not higher than in the control subjects carrying no risk alleles for
IDDM.
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Our results suggest that a subgroup of patients with newly diagnosed
IDDM has significant responses to CVB4, supporting the involvement of
enteroviral infections in the development of IDDM in these patients.
5.3 Cellular immunity to GAD in IDDM (III)
5.3.1 T-cell proliferation response to GAD in IDDM
Median SI to GAD was 3.10 in patients with IDDM compared to 1.55 in control
subjects (p=0.03; Mann-Whitney U test) (Figure 4). Multiples of medians in the
control group were used as the cut-off for positivity because of the skewed
distribution of SIs in the groups. An enhanced proliferative response to GAD65
was found in 14 of 35 (40%) patients with IDDM and in five of 32 (15.6%)
control children (p=0.03; Fisher’s exact test), when the cut-off for positivity was
three multiples (SI≥4.65) of the median SI in healthy children. When four
multiples of the median (SI≥6.2) was used as the cut-off point, nine patients and
two controls had an SI above this limit (p=0.05; Fisher’s exact test).
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Figure 4. T-cell proliferation response to GAD expressed as stimulation indexes (SI) in
patients with newly diagnosed IDDM and in control children. The cut-off level for
positivity determined as three multiples of median SI in the control subjects is marked
with a horizontal line.
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Our finding of enhanced cellular reactivity to GAD in patients with newly
diagnosed IDDM is in accordance with previous studies (Atkinson et al. 1992,
Durinovic-Bello et al. 1996). Although the T-cell reactivity to GAD was
significantly higher in the patients with newly diagnosed IDDM, such an activity
was also detectable in a proportion of the control children (16%) in our study. No
previous data exist on the T-cell reactivity to GAD in extensive series of young
healthy children without IDDM relatives. Atkinson et al. (1992) found no T-cell
responses to GAD above an SI of 2.7 in any of their healthy controls, but their
control group included no children, and the study by Durinovic-Bello et al.
(1996) comprised mostly young adults and only four children as controls. The
result of the T-cell workshop presented at the Immunology of Diabetes Society
(IDS) meeting in Canberra, Australia (1995), in which T cell responses to GAD
were often found in healthy subjects, supports our observation of GAD reactivity
in unaffected children.
In ICA-positive relatives a tendency towards a more frequent
responsiveness in the youngest subjects could be seen in the study of Harrison et
al. (1993). In our hands, T-cell reactivity to GAD tended to be more common in
healthy children than in healthy adults; T-cell reactivity to GAD was seen in three
of 28 (11%) healthy adults (median SI was 1.0, cut-off point for positivity was
SI=3.0) as reported in paper IV.
5.3.2 Relationship between cellular and humoral immunity to GAD in IDDM
Fifty-seven (69%) of the 82 patients with IDDM and none of the 63 controls
tested positive for GADA (GADA≥5.35 RU). There was no correlation between
GADA and T-cell response to GAD (r=0.09; p=0.60; Figure 5) or to CVB4 in the
patients with IDDM (r=-0.20, p=0.10). Positive GADA and/or T-cell response to
GAD was observed in 77.1% of the patients, and both responses occurred
together in nine of the 35 patients (25.7%) tested for both cellular and humoral
immunity to GAD.
It has been reported that the cytokines secreted by Th1 cells, such as IFN-
γ, are inhibitory to B-cell proliferation and antibody production in vitro (Del Prete
et al. 1991), but in vivo immunization as a rule results in both antigen-specific B-
and T-cell responses. When the T-cell response to TT was related to TT antibody
levels we found a weak positive correlation in the patients with IDDM and no
correlation in the control subjects. Autoimmunity to GAD seems to differ from
immunization to TT. An inverse correlation between GADA and T-cell reactivity
to GAD has been reported in subjects at high risk of IDDM (Harrison et al.
1993), but no reports have been published on IDDM patients.
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Figure 5. Relation of T-cell
response to GAD and GADA
in patients with newly
diagnosed IDDM (r=0.09,
p=0.60) () and in control
children ().
In the present study, in the patients with IDDM, the highest cellular and
humoral responses to GAD did not occur in the same individuals, suggesting a
dichotomy of cellular and humoral immune responses, but this observation did
not reach statistical significance.
5.3.3 Relation between T- cell response to GAD and CVB4 in IDDM
A positive correlation was found between the T-cell response to GAD and that to
CVB4 in patients with newly diagnosed IDDM (n=27, r=0.62, p=0.001; Figure
6), while no correlation was observed between T-cell responses to GAD and PV1
or TT (p=0.10 and p=0.35, respectively). Control children showed no correlation
between SIs to GAD and CVB4 (n=17, r=0.23, p=0.38; Figure 6).
At the cellular level the major determinant of GAD recognized by T cells
from those at risk for IDDM has been reported to be the region containing amino
acids 247-279, a stretch with sequence similarity with the 2C protein of CVBs
(Atkinson et al. 1994). Several studies have shown, however, that T-cell
immunity to GAD is not restricted to the PEVKEK epitope in IDDM. Lohmann
et al. (1994) reported a different immunodominant T-cell epitope (473-555)
recognized in IDDM patients more often than in controls. Endl et al. (1997)
raised T-cell lines from IDDM patients against GAD and did not find T cells
responding to epitopes containing identical sequences to coxsackievirus protein
2C. In addition, T-cell reactivity to two peptides sharing sequence similarity with
CVBs (PEVKEK) was not primarily associated with IDDM, as unaffected control
subjects also recognized the two GAD peptides (Schloot et al. 1997).
Because the purified virus antigen which we used in the present study did
not contain the non-structural protein 2C carrying the homology sequence, the
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Figure 6. Correlation
between T-cell response to
GAD and CVB4 in patients
with newly diagnosed IDDM
(r=0.62, p=0.001) () and in
control children (r=0.23,
p=0.38) ().
correlation between T-cell responses to GAD and to CVB4 observed in vitro in
our study cannot be explained by the occurrence of cross-reactive autoimmunity
to this GAD epitope in IDDM. However, it is possible that in vivo an immune
response to GAD may be activated by exposure to CVB4 containing sequence
homology. On the other hand, the immune response to GAD may be activated by
other mechanisms than molecular mimicry during CVB4 infection. Recently
Horwitz et al. (1998) showed that the islet sensitization and development of
IDDM in an animal model was an indirect consequence of the viral infection and
not caused by molecular mimicry. It is also possible, that if GAD-reactive
lymphocytes belong to the gut-associated lymphocyte population, as suggested in
paper V, an enterovirus infection may stimulate the autoreactive lymphocyte
population by a bystander effect when the virus replicates in the gut mucosa and
causes changes in the cytokine environment of the gut immune system.
5.4 Cellular immunity to GAD in APECED (IV)
5.4.1 T-cell proliferation response to GAD in APECED
Fifteen of the 44 (34%) patients with APECED compared to three of the 28
(11%) healthy adult controls had a positive proliferation response to GAD (10
µg/ml) when three multiples of median SI (SI ≥ 3) in the control group were used
as the cut-off for positivity (p=0.03, Fisher’s exact test). The distribution of the
SIs to GAD differed significantly between the patients and the controls; median
(range) was 1.6 (1-40) for the patients and 1.0 (1-13.9) for the controls (Figure
7A; p=0.004; Mann-Whitney U test).
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T-cell proliferation response to the control antigen AChE was studied in
ten subjects, 5 of whom had a positive T-cell response to GAD (SI ≥ 3). Only one
patient showed a positive proliferative response to AChE (SI=5.9). None of the
16 individuals tested with the extract of sf9 cells infected with baculovirus at a
concentration of 0.1 µg/ml and one of the 20 individuals tested at a concentration
of 1.0 µg/ml showed positive response (SI ≥ 3) to this control antigen.
Cellular immunity to GAD in APECED has not been reported previously.
We demonstrate that autoimmunity to GAD is a common feature in APECED and
not restricted to the subgroup of the patients with IDDM (see chapter 5.4.4)
indicating that not only antigen-specificity but also other determinants of
autoreactivity are important in the development of autoimmune IDDM. However,
the pathogenesis of IDDM in APECED may differ from that in common IDDM
because of the single gene defect in APECED.
0
10
20
30
40
APECED
without
IDDM
ControlsAPECED
with
IDDM
APECED
with
preIDDM
A
SI
 to
 G
A
D
0
400
2000
4000
6000
8000
10000
12000
14000
APECED
without
IDDM
ControlsAPECED
with
IDDM
APECED
with
preIDDM
400
B
IF
N
-γ
 (p
g/
m
l)
Figure 7. Cellular reactivity to GAD in patients with APECED and in healthy adults
detected as proliferation response of PBMCs to GAD (A) or IFN-γ secretion by GAD-
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reactive T cells (B). The cut-off level for positivity (SI = 3.0) determined as three
multiples of median SI in the control group is marked with a horizontal line (A).
In patients with APECED we found proliferation response to GAD in five
of the seven (71%) patients with DQB1*0201/x, in four of the 11 (36%) patients
with DQB1*0302/x, and in only five of the 23 (22%) patients without any risk
allele. Positive proliferation response against GAD was significantly more
common among the DQB1*0201 allele positive patients than those without the
risk alleles for IDDM (p=0.03; Fisher’s exact test). It should be emphasized that
in this series of APECED patients four of seven patients with HLA DQB1*0201
allele were positive for DR7, which is not associated with an increased genetic
risk for ”conventional” IDDM. Others have reported that antibodies to GAD were
associated with the HLA DQB1*0201 allele (Hagopian et al. 1995) or with DR3
(Genovese et al. 1996), which is in linkage disequilibrium with DQB1*0201.
Harrison et al. found an association between both humoral and cellular immune
response to GAD67 and HLA DR3 in their study on first-degree relatives of
IDDM patients (Harrison et al. 1993).
5.4.2 IFN-γ secretion by GAD-reactive T cells in APECED
A subgroup of 29 patients with APECED and 21 control subjects was studied for
IFN-γ secretion by GAD stimulated T cells. Secretion of IFN-γ (≥ 50 pg/ml) by
GAD stimulated PBMCs was found in 17 of 29 (59%) patients tested (Fig. 7B),
and in four of 21 (19%) healthy people studied (p=0.008, Fisher’s exact test). The
levels of GAD stimulated IFN-γ were high in the patients (median 179 pg/ml,
range 0-12.5 ng/ml) and different from the levels seen in the controls (median 0,
range 0-209 pg/ml) (p=0.001, Mann Whitney U test). In contrast, IFN-γ secretion
by TT stimulated T cells tended to be lower in the patients with APECED than in
the control subjects (p=0.09, Mann-Whitney U test).
Both the proliferation response and IFN-γ secretion by GAD stimulated T
cells occurred in five cases, only proliferation in three cases, only IFN-γ secretion
in 12 cases, and neither in nine cases. The levels of IFN-γ by GAD stimulated
PBMCs did not differ between the patients with positive (SI≥3) or negative
(SI<3) proliferation response to GAD (p=0.85, Mann-Whitney U test). No
correlation existed between the proliferation response to GAD and the
concentration of IFN-γ secreted by the GAD stimulated PBMCs (r=-0.081,
p=0.68), whereas a positive correlation was seen between the T-cell proliferation
response to TT and IFN-γ secretion by TT-stimulated T cells (r=0.741, p=0.009,
Spearman’s correlation).
IFN-γ secretion by GAD stimulated T cells was seen in several patients
without detectable proliferation response to GAD. T cell proliferation reflects the
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summation of several signals, and activation of lymphokine genes after
stimulation with a specific antigen may occur without proliferation (Evavold et
al. 1993, Halminen et al. 1997). GAD induced secretion of IFN-γ in the absence
of T-cell proliferation in patients with APECED indicates the presence of specific
T lymphocytes recognizing the antigen. In adults immunized against tetanus in
childhood, a weak responsiveness to a recall antigen is sometimes detected only
as activation of cytokine secretion without proliferation response (Halminen et al.
1997).
In the present study GAD stimulated T-cell proliferation was associated
with the HLA DQB1*0201 allele, but the secretion of IFN-γ or GAD Ab was in
no relation to the HLA DQB1 alleles. In this regard DQB1*0201 may not be a
restrictive element for the recognition of GAD.
5.4.3 Relationship between cellular and humoral immunity to GAD in
APECED
In patients with APECED, positive GADA were present in 14 of the 44 patients
(32%). A negative correlation (r=-0.436, p=0.03) existed between GADA and the
SIs to GAD among the patients who responded to GAD (SI ≥ 3 or GADA ≥ 5;
Figure 8). Similarly, the concentration of IFN-γ in the supernatants from the
GAD stimulated PBMCs in patients with APECED showed an inverse correlation
(r= -0.366) with the levels of GADA among the responders (IFN-γ ≥ 50 pg/ml or
GADA ≥ 5), although this was not statistically significant (p=0.12). The inverse
correlation between the levels of antibodies to GAD and the SIs to GAD existed
only among the subgroup of APECED patients without IDDM (r=-0.714,
p=0.001), whereas in the subgroup of APECED patients prone to IDDM (eight
patients with clinical IDDM and three prediabetic patients) no correlation was
seen (r=0.171, p=0.69, Table 2). TT Ab levels did not show any correlation with
SIs to TT in the patients with APECED or in the control subjects ( r=-0.005,
p=0.98 and r=0.129, p=0.62, respectively).
Coincidence of both cellular and humoral responses to GAD in the same
patient was infrequent occurring in only four of the 44 patients. An inverse
correlation between humoral and cellular immunity to GAD was observed. There
was also a tendency for an inverse correlation between the concentration of IFN-γ
secreted by GAD-stimulated T cells and the level of antibodies to GAD. An
inverse correlation between GADA and T-cell reactivity to GAD has been
reported in subjects at high risk of IDDM (Harrison et al. 1993), but in contrast to
the hypothesis suggested by Harrison et al., the T cell response to GAD did not
seem to be associated with clinical IDDM in these patients (see chapter 5.4.4).
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Figure 8. Relation of T cell
proliferation response to
GAD and GADA in patients
with APECED without
IDDM (), with IDDM (),
and in the patients who
developed IDDM within 12
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5.4.4 Relation of IDDM, insulin secretion and autoimmunity to GAD in
APECED
Eight of the 44 patients (18%) had IDDM diagnosed already years before the T
cell testing. The patients with IDDM did not differ from the nondiabetic patients
with respect to T cell proliferation, IFN-γ secretion by the PBMCs, or antibody-
positivity to GAD (Table 2).
Of the 14 nondiabetic patients who underwent intravenous glucose
tolerance test (IVGTT), six had a positive proliferation response to GAD. There
was no difference between patients with positive and those with negative
proliferation response in either the 1+3 minute or 10 minute incremental insulin
area under the curve (AUC) during IVGTT. The median (range) of 3’ and 10’
insulin AUC was 85.5 (28-444) and 312 (107-1790) for the patients with SI<3
(n=7) and 56.5 (18-465) and 282 (63-2039) mU/l for the patients with SI≥3
(n=6). IFN-γ secretion by GAD stimulated PBMCs was associated neither to
decreased 3’ nor 10’ insulin AUC during IVGTT although the number of patients
in this analysis was small (n=9; data not shown).
Of the three patients who developed diabetes within 12 months after
testing, one had both positive antibody and proliferation response to GAD,
another had only positive antibody response, and the only one who was studied
for IFN-γ secretion by GAD stimulated PBMCs had no antibody or proliferation
response but showed low IFN-γ secretion (86 pg/ml).
Our results indicate that most patients with APECED (76%) develop
autoimmunity to GAD detected as antibodies, T-cell proliferation or GAD
stimulated IFN-γ secretion by T cells. This suggests that immunization to GAD in
APECED may be a more common phenomenon than previously thought.
57
Actually, in the present study T-cell reactivity to GAD was found in the majority
of APECED patients without evidence of IDDM. Since in our series, all patients
with IDDM had had the disease already for several years before T-cell testing, it
is possible that we could not see the association of GAD reactivity with IDDM
because the reactivity had declined after the diagnosis. When patients with
decreased insulin response in IVGTT were studied, T-cell reactivity to GAD did
not show association with this parameter of β-cell dysfunction either.
Others have reported high prevalence of GAD antibodies in APECED
whether the patients develop IDDM or not (Björk et al. 1994, Tuomi et al. 1996),
and further, it has been reported that the islets of nondiabetic, autoimmune,
polyendocrine patients lack immunohistological changes despite the occurrence
of GAD antibodies (Wagner et al. 1994). It thus seems that autoimmunity to
GAD does not directly imply clinically detectable β-cell damage in patients with
APECED, although based on the present study, the occurrence of subclinical,
nondestructive insulitis cannot be excluded.
Table 2. Autoimmunity to GAD and the frequencies of HLA DQB1*0201 and 0302
alleles in APECED patients with IDDM, prediabetic patients and patients without
IDDM. SI ≥ 3 is considered as a positive proliferation response and GADA level ≥ 5 as
a positive humoral response (GADA+). No significant differences were found in the
frequencies of positive cellular or humoral immunity to GAD or in the frequencies of
HLA DQB1 genotypes between the patients with IDDM, prediabetic patients and the
patients without IDDM.
APECED with
IDDM
APECED with
preIDDM
APECED without
IDDM
SI to GAD ≥ 3 3/8 (38%) 1/3 (33%) 11/33 (33%)
GAD-IFN-γ ≥ 50 pg/ml 3/5 (60%) 1/1 (100%) 13/23 (57%)
GADA+ 4/8 (50%) 2/3 (67%) 8/33 (24%)
HLA DQB1
*0201,x
*0302,x
*x,x
1/8 (13%)
2/8 (25%)
5/8 (63%)
2/3 (67%)
0/3 (0%)
1/3 (33%)
4/30 (13%)
9/30 (30%)
17/30 (57%)
Correlation between SI
to GAD and GADA
r=0.171, p=0.83
(in patients with IDDM or preIDDM)
r=-0.714, p=0.001
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5.5 Proliferation response to GAD after depletion of α4β7-expressing
PBMCs (V)
The treatment with monoclonal antibody against α4β7 depleted the α4β7high
population of PBMCs. The changes in the α4β7-expressing CD4 and CD8
lymphocyte populations in a representative case are shown in Figure 4, paper V.
Proliferation to GAD and TT after depletion of α4β7high expressing PBMCs was
studied in six patients with newly diagnosed IDDM and in one subject at high
risk for IDDM.
A marked decrease in the proliferation response to GAD (expressed as
cpm) was found in three of the patients with IDDM and in the subject at high risk
for IDDM, the decrease being 93, 60, 45, and 84%, respectively (Figure 9A). A
marked increase in the proliferation to TT was found in four patients at 154, 79,
368, and 160%, respectively (Figure 9B).
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Figure 9. Proliferation response of PBMCs (black bars) and α4β7-depleted PBMCs
(hatched bars) to GAD (A) and TT (B) in six patients with newly diagnosed IDDM and
in one subject at risk for IDDM (5), and in three patients with APECED (C, D). Case 3
also had IDDM. Data are expressed as median cpm ± SD calculated from quadruplicate
wells. A change of more than 30% in proliferation is marked with an asterisk.
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A decrease of 37% in the proliferation response to GAD was seen in the
one patient with APECED who had IDDM, whereas in the two non-diabetic
APECED patients no change in the responsiveness was found (Figure 9C). A
marked increase in proliferation response to TT was found in two APECED
patients (Figure 9D).
The cellular response to GAD decreased markedly after the depletion of
α4β7-expressing cells indicating that a remarkable proportion of these islet cell
antigen reactive T cells express α4β7-integrin, which is associated with
recirculation of lymphocytes to gut lymphoid tissue. In contrast, the reactivity to a
parenteral antigen TT increased, indicating that these two antigen-specific T cell
populations show distinct homing properties.
Besides the specificity of T cells to the autoantigen, the sites of the
priming and expansion of antigen-specific lymphocytes are important in the
development of organ-specific autoimmune disease. In NOD mice, binding of
lymphocytes to endothelium in inflamed islets includes the adhesion molecule
MAdCAM-1, a ligand for the gut homing receptor α4β7-integrin. MAdCAM-1 is
expressed in the islets at early stages of insulitis (Hänninen et al. 1993b, Faveeuw
et al. 1994, Yang et al. 1994), and further, most of the lymphocytes infiltrating
the islets in NOD mice expressed both α4 and β7 molecules, whereas only some
of the lymphocytes expressed L-selectin at the early stages of insulitis (Hänninen
et al. 1993b). Treatment with monoclonal antibodies to α4 protected against
insulitis (Yang et al. 1994), which further supports the importance of α4β7-
expressing lymphocytes in IDDM.
The GAD reactivity was not totally abolished in IDDM patients when
α4β7-expressing lymphocytes were depleted. In three IDDM patients the
reactivity to GAD did not decrease after depletion of α4β7-expressing
lymphocytes. In NOD mice the role of mucosa-associated (β7 high) lymphocytes
is proposed to be important especially at the beginning of insulitis (Hänninen et
al. 1996). Thus it was not unexpected that at the time of diagnosis, obviously
after long-lasting insulitis, the GAD reactivity was not restricted to the α4β7-
expressing lymphocytes. In sites of chronic inflammation, several endothelial
adhesion molecules are induced and lymphocytes expressing different homing
receptors infiltrate inflamed tissue. Studies on prediabetic subjects would give
more information about the role of gut-associated lymphocytes in the initiation of
the immune response to β-cells.
Although the number of APECED patients was small in the present study,
the GAD-reactive lymphocytes from the APECED patient with IDDM expressed
α4β7-integrin, but lymphocytes from the two non-diabetic patients did not show
high expression of gut-specific homing receptor. With regard to the importance
of homing receptors in organ-specific autoimmune diseases, the GAD-reactive
lymphocytes in Stiff-man syndrome or in APECED may not have homing
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properties to gut-associated sites, and for that reason do not infiltrate the pancreas
(Wagner et al. 1994, Ellis and Atkinson 1996).
Our results do not indicate whether the priming site of GAD-specific
lymphocytes is the gut or the pancreas. However, these results imply that the T
cell repertoire reactive against an islet cell antigen in human IDDM seems to
recirculate via the gut and is there exposed to local cytokines. The development
of functionally different T cell subtypes is dependent on the cytokine
environment in which the cell population differentiates (De Carli et al. 1994).
Thus changes in the cytokine profile in the gut as a result of various stimuli may
induce the development of autoaggressive lymphocyte clones infiltrating the
pancreatic islets.
In conclusion, this study demonstrates that islet cell reactive lymphocytes
in human IDDM express the gut-specific homing receptor α4β7-integrin.
Accordingly, stimulation or suppression of the gut immune system may have an
important role in the development of autoimmunity against pancreatic β-cells.
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6. GENERAL DISCUSSION
It is currently widely accepted that T cell mediated immunity against pancreatic
β-cells plays a crucial role in the pathogenesis of IDDM. Thus T cell assays to
detect and characterize cellular reactivity against diabetes-associated
environmental as well as autoantigens are needed. Reports on aberrant cellular
reactivity to diabetes-associated foreign and self antigens have been published
(Roep 1996, Åkerblom and Knip 1998). However, several discrepancies in the
observations have raised the question of the standardization of T cell assays in
IDDM. The first T-cell workshop on cellular reactivity against several
autoantigens and control antigens was finished recently, and the results were
discussed at the third Immunology of Diabetes Society conference held in
Chicago in June 1998. In this workshop a series of candidate antigens and some
control antigens were distributed blindly to 26 laboratories world-wide for the
analysis of 10 newly diagnosed IDDM patients and 10 non-diabetic control
subjects. The results showed that only a few laboratories could distinguish IDDM
patients from non-diabetic subjects with regard to proliferative responses to
individual islet autoantigens, but generally no differences between the groups
could be seen (Roep 1999). Thus the results indicated that the field of T cell
immunity is a difficult area, and some of the problems were identified. One of
them was the quality of the autoantigen preparation.
In the present thesis considerable attention was paid to the quality of the
GAD preparations. The purity of GAD preparations was controlled as described,
and the endotoxin content found to be under the detection limit of a commonly
used test. T cell reactivity to a control protein produced by protocol similar to
GAD, and to a lysate of baculovirus infected Sf9 cells were found to be absent or
low. In addition, in patients with APECED an inverse correlation was found
between T cell response to GAD and GADA. These findings together indicate
that the observations of enhanced T cell reactivity to GAD in patients with IDDM
and in patients with APECED can be considered reliable.
It seems that T cell responses to autoantigens in general are more difficult
to measure than those against non-self proteins, perhaps due to relatively low
precursor cell frequencies or regulatory immune responses directed to control
autoreactivity (Roep 1999). In our hands, T cell proliferation responses to TT
were found to correlate well with IFN-γ levels secreted by TT-stimulated cells
both in healthy subjects (Halminen et al. 1997) and in patients with APECED
(paper III). In the patients with APECED, IFN-γ secretion by GAD stimulated T
cells was often seen without detectable response in the proliferation assay,
suggesting that the measurement of IFN-γ may be a more sensitive way to detect
reactivity to autoantigens. Perhaps the T cell proliferation assays as they are
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currently performed are not optimal to detect and characterize autoreactive T
cells in IDDM, and thus the development of novel approaches, such as the use of
cytokine measurements, ELISPOT, limiting dilution analyses etc., should be
considered.
Triggers of the gut immune system, such as dietary proteins and
enteroviruses have been associated to the risk for IDDM. The observed enhanced
cellular reactivity to BLG, wheat gluten and CVB4 in the present study is in
accordance with multiple studies showing enhanced humoral and cellular
reactivity to dietary and viral antigens in IDDM. Pathogenic mechanisms based
on molecular mimicry between CM or viral proteins and islet cell proteins have
been proposed (Karjalainen et al. 1992, Kaufman et al. 1992, Cavallo et al. 1996,
Honeyman et al. 1998), but there is no direct evidence that immunity to these
proteins would be pathogenic in IDDM. Alternatively, the enhanced immune
responsiveness to dietary antigens in patients with IDDM could be explained by a
broken tolerance to oral antigens in general. It is thus possible that none of these
dietary proteins may be directly involved in the pathogenesis of IDDM but that
enhanced immunity to them is rather a consequence of dysregulation of oral
tolerance in IDDM. This regulatory defect of the gut immune system may
actually have a fundamental role in the pathogenetic process leading to β-cell
destruction and overt IDDM.
These studies showed that islet cell antigen GAD reactive lymphocytes in
patients with newly diagnosed IDDM expressed the gut-specific homing receptor
α4β7-integrin, whereas reactivity to TT, a parenteral antigen, was found in
lymphocytes expressing low levels of α4β7-integrin. This result is analogous to
the situation with a natural rotavirus infection caused by an enteric pathogen, in
which a specific circulating memory CD4+ response was largely limited to the
gut-homing α4β7+ memory T cell population (Rott et al. 1997). Thus the finding
of the high expression of α4β7-integrin in GAD-reactive T cells demonstrates a
link between the gut immune system and autoreactivity against pancreatic islets
in humans, and further emphasizes the role of the gut immune system in the
pathogenesis of IDDM.
Enhanced reactivity to an enterovirus, CVB4, may reflect preceding
enteroviral infections, or alternatively, it is possible that if GAD-reactive
lymphocytes belong to the gut-associated lymphocyte population, an enterovirus
infection may stimulate the autoreactive lymphocyte population by a bystander
effect when the virus replicates in the gut mucosa and causes changes in the
cytokine environment of the gut immune system. The hypothesis of the role of the
gut immune system in the development of IDDM is supported by the results
presented in papers I, II, III and V of this thesis.
Cellular autoreactivity to GAD detected as proliferation response to GAD
or IFN-γ secretion by GAD reactive T cells was a common phenomenon in
patients with APECED and not restricted to the patients with IDDM. Cellular
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reactivity to GAD was also seen in a subgroup of control subjects. These findings
suggest that islet cell reactive T cells are present in these individuals without
clinical IDDM. Reports on increased levels of autoantibodies to islet cells in
healthy individuals without clinical disease have been published earlier (Adojaan
et al. 1996) indicating that deletion of islet cell reactive lymphocytes is not
complete in humans. However, autoantibodies or in vitro detectable T cell
reactivity to GAD do not appear to be harmful as such, suggesting that
characteristics other than antigen-specificity may be needed for the development
of clinically significant β-cell destruction.
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7. SUMMARY AND CONCLUSIONS
Occurrence of cellular immunity to dietary and viral proteins as well as to the
islet cell antigen GAD, was studied in patients with IDDM, in patients with
APECED and in control subjects. The relationship of T-cell reactivity to antibody
responses against these antigens was analyzed. The immune responses were
further analyzed with respect to the HLA DQB1 risk alleles for IDDM in the
study subjects. Characteristics of T lymphocytes reactive to GAD were analyzed
by measuring the cytokine production by GAD reactive cells and by studying the
expression of the gut-specific homing receptor α4β7-integrin in these cells.
Finally, association of cellular reactivity to GAD with IDDM and β-cell function
was studied in patients with APECED.
Enhanced cellular reactivity to BLG, wheat gluten and CVB4 were found
in patients with newly diagnosed IDDM. None of these responses were associated
to any HLA DQB1 risk allele for IDDM in the study subjects, suggesting that
these enhanced responses may not be a secondary phenomenon of the excess of
specific HLA types in patients with IDDM, but rather are associated with IDDM
as such. The observed enhanced responsiveness to dietary proteins suggests that
the regulation of mucosal immunity may be disturbed in IDDM. The enhanced
responsiveness to CVB4 supports the involvement of enteroviral infections in the
development of IDDM.
Autoimmunity to GAD, measured as the T cell proliferation response,
IFN-γ secretion by GAD-specific T cells or antibodies to GAD, was seen in the
majority of the patients with APECED. Antibody and cellular responses to GAD
showed an inverse correlation in these patients, indicating a reciprocal regulation
of these responses. Neither humoral nor cellular autoimmunity was restricted to
the APECED patients with IDDM. Association of cellular reactivity to GAD with
β-cell dysfunction was further studied by performing IVGTT in a subgroup of
patients with APECED, but no such association was found. It is concluded that
autoimmunity to GAD does not directly imply clinically detectable β-cell damage
in patients with APECED, although the occurrence of a subclinical,
nondestructive insulitis can not be excluded.
T cell responses to GAD were found in 40% of patients with newly
diagnosed IDDM. GAD-reactive lymphocytes were demonstrated to express the
gut-specific homing receptor α4β7-integrin in patients with newly diagnosed
IDDM, in a prediabetic subject and in an APECED patient with IDDM, whereas
reactivity to TT, a parenteral antigen, was found in lymphocytes expressing low
levels of α4β7-integrin. Although these results do not indicate whether the
priming site of GAD-specific lymphocytes is the gut or the pancreas, they imply
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that the T cell repertoire reactive to an islet cell antigen in human IDDM seems to
recirculate via the gut and is there exposed to local cytokines.
In conclusion, enhanced cellular reactivity against several triggers of the
gut immune system, such as dietary proteins and CVB4, suggests that regulation
of mucosal immunity in patients with IDDM is altered. Findings in patients with
APECED suggest that autoimmunity to an islet cell antigen does not imply
clinically detectable β-cell damage, indicating that characteristics other than
antigen-specificity, e.g. homing properties of autoreactive T cells, are also
important. The finding that GAD reactive T cells have gut specific homing
properties emphasizes the importance of the gut immune system in the
pathogenesis of IDDM. Accordingly, stimulation or suppression of the gut
immune system may have an important role in the development of autoimmunity
against pancreatic β-cells.
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